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CHAPTER I 
 
 
INTRODUCTION 
 
Mental Retardation 
 Determining the genetic causes of mental retardation (MR), and their 
intersection with environmental factors, is currently one of the greatest 
challenges in medical genetics. Recently, current practice has adopted using the 
euphemism “intellectual disability” when referring to MR (Rosa’s Law, 2010). 
However, intellectual disability is a much broader diagnosis and includes deficits 
that are too mild to qualify as mental retardation, or too specific, or acquired later 
in life due to injury or degenerative disease, rather than developmental delay. 
Therefore, I use the term MR [International Classification of Diseases, (ICD 317-
319); Diagnostic and Statistical Manual of Mental Disorders, (DSM)] to define a 
developmental disability characterized by significant limitations in cognitive 
function and adaptive behavior, as expressed in conceptual, social, and practical 
adaptive skills, which manifests as a depressed developmental trajectory prior to 
18 years of age (Chelly et al., 2006). MR consists of an intelligence quotient (IQ) 
<70, compared to the scaled average IQ in the general population of 100. The 
prevalence of MR in developed countries is 2-3% of the population (Leonard and 
Wen, 2002). On the basis of IQ, classification is divided into two main categories: 
mild MR with an IQ between 50-70 and severe MR with an IQ below 50. MR 
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causes are extremely heterogeneous and can result from environmental and 
genetic causes, or the intersection of the two factors (Fig. 1). MR environmental 
causes include prenatal exposure to toxic substances such as alcohol, 
environmental contaminants and infection. MR genetic factors include 
chromosomal abnormalities (numerical and partial chromosome duplications, and 
deletions) and monogenic disorders (autosomal dominant, autosomal recessive, 
X-linked) (Curry et al., 1997). Overall, however, the cause is known only in ~50% 
of cases with moderate to severe MR, and an even lower percentage of patients 
with mild MR. The higher prevalence of MR among male children is well known 
(Drews et al., 1995; Richardson et al., 1986). Males are 1.6 to 1.7 times more 
likely to experience both mild and severe forms of MR compared to their female 
cohorts. The relative risk in males for mild MR is 1.9 times greater than for 
severe MR (Croen et al., 2001). This sex differential shows that X-linked gene 
defects are a major cause of MR.  
 
X-linked Mental Retardation 
 X-chromosome linked mental retardation (XLMR) is subdivided into 
syndromic (S-XLMR) and non-syndromic (NS-XLMR) forms, depending on 
whether further abnormalities (in addition to MR) occur in the patient (Lehrke, 
1972; Ropers and Hamel, 2005). S-XLMR is amenable to conventional genetic 
mapping strategies because families sharing clinical symptoms can be pooled for 
linkage analysis to define candidate chromosomal intervals. In contrast, NS-
XLMR is not associated with a specific set of clinical or metabolic symptoms and  
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Figure 1. Overview of mental retardation causes. Chromosomal abnormalities 
(12%); Subtelomeric abnormalities (6%); Fragile X syndrome (1%); Other known 
syndromes (3%); Environmental causes (25%); Metabolic causes (3%); 
Unknown causes presumed to be genetic (25%); Unknown causes presumed to 
be environmental (25%). Figure adapted from (Winnepenninckx, et al., 2003). 
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generally exhibits high gene background heterogeneity (Chelly and Mandel, 
2001). In this case, linkage results cannot be pooled, even from families in which 
MR genes map to overlapping regions, because these families might carry 
mutations in different genes. Around two-thirds of XLMR cases are thought to be 
non-syndromic (Fishburn et al., 1983) and therefore their molecular elucidation is 
extremely difficult. However, mutations in several XLMR genes can give rise to 
both non-syndromic and syndromic forms, indicating there is not a consistently 
reliable molecular basis for strictly distinguishing between S-XLMR and NS-
XLMR (Ropers and Hamel, 2005). Genes implicated in NS-XLMR include FMR2 
(transcriptional regulator; long-term memory), DLG3 (postsynaptic scaffolding 
protein) and PAK3 (actin cytoskeleton regulator; neurite outgrowth) (Ropers, 
2006). About 140 syndromic forms of XLMR have been described to date. In ~66 
of these cases, the causative genetic defects have been identified, and in ~50 
others, the underlying defect has been mapped to a specific region on the X 
chromosome (Ropers and Hamel, 2005). Genes involved in S-XLMR include 
RSK2 (Coffin-Lowry syndrome; associated with mental impairment, cardiac and 
growth abnormalities), MECP2 (Rett syndrome; Angelman and Prader-Willi-like 
phenotypes; associated with cognitive and developmental delay; jerky 
movements; hand-flapping), and FMR1 (Fragile X syndrome (FXS); associated 
with mental retardation and autism) (Ropers, 2006). A more thorough summary 
of XLMR genes is shown in Fig. 2.  
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Figure 2. X chromosome causative MR genes. XLMR genes identified by 
mutation screening or by studying patients with chromosome rearrangements (in 
red). Italics denote candidate genes. Adapted from (Ropers, 2006). 
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Autism Spectrum Disorders 
 Autism spectrum disorder (ASD) was first described in the early 1940s by 
psychiatrists Kanner in the United States, reviewed in (Kanner, 1971) and 
Asperger in Austria (Asperger, 1944). ASD is a highly heterogeneous genetic 
disorder with heritability indices of 0.85-0.92 (Monaco and Bailey, 2001; Smalley 
et al., 1988). Findings from a comprehensive genetics evaluation have previously 
reported that a Mendelian chromosomal cause, or at least pre-disposition, occurs 
in 15-40% of children who fit the ASD behavioral diagnostic criteria (Schaefer 
and Mendelsohn, 2008). The Centers for Disease Control and Prevention have 
reported ASD diagnosis in the United States in 1/91 for 3-17 year old children 
(Kogan et al., 2009). Most epidemiological analyses indicate that the apparent 
‘autism epidemic’ does not reflect a true increase in ASD incidence, but rather an 
increased awareness by both the public and medical establishment, leading to 
more complete case findings together with broadening of the diagnostic criteria 
(Shattuck, 2006a; Shattuck, 2006b).  
 ASD is clinically defined on the basis of three behavioral symptoms: 1) 
impairment in social interactions, 2) lack of communication and 3) the propensity 
for repetitive behavior (American Psychiatric Association. Diagnostic and 
Statistical Manual of Mental Disorders). Typically, autistic children do not seek or 
provide comfort to others, often ignoring others around them. Children with 
autism fail to develop friendships with peers and siblings, and reciprocal 
communication, through speech, gestures, or facial expressions, is impaired. 
Children usually do not recognize the concept that speech can be used to name 
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objects, request a toy or to engage others (Miles, 2011). ASD typically develops 
before the age of 3, and most ASD children are not diagnosed until after their 
second year of age when language delays become obvious. However, ASD 
onset is typically gradual: ~30% of ASD children have a ‘regressive’ onset in 
which they gradually lose language and become more distant (Miles, 2011). 
There is much debate on whether these children are normal and then become 
abnormal by some exogenous environmental exposure. However, the best 
evidence, including retrospective analysis, suggests the regressive course is 
genetically determined (Anderson et al., 2007; Lord et al., 2004; Stefanatos, 
2008). Approximately 25% of children who fit the ASD diagnostic criteria between 
the ages of 2-3 subsequently begin to talk and communicate by the age of 7 and 
are able to function, at some level, in the regular school population. For the 
remainder, most have limited improvement with age, and continue to require 
parent, school and societal support throughout life (Seltzer et al., 2004).  
 Using medical genetic evaluation techniques, a genetic cause can be 
identified in 20-25% of children on the autism spectrum (Miles, 2011). For the 
remaining 75-80% of cases, there is no identified cause. Genetic causes of 
autism are classified as cytogenetically visible chromosomal abnormalities 
(~5%), copy number variations (CNVs) (10-20%), and single-gene disorders 
(~5%). Maternally derived 15q duplications of the imprinted Prader 
Willi/Angelman region are the most commonly observed chromosomal 
abnormalities associated with autism; detected in 1-3% of cases. These 
duplication events are mediated by unequal homologous recombination involving 
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clustered low copy repeats (Wang et al., 2008). The most common CNVs related 
to autism are 15q11.2-11.3 duplications and reciprocal 16p11.2 microdeletions 
and duplications, which are located at a hot spot of genomic instability caused by 
duplicated blocks of DNA, leading to unequal crossing over during meiosis 
(Fernandez et al., 2010; Shinawi et al., 2010). Most CNVs arise de novo and 
therefore cannot account for familiality. Often, when CNVs are inherited, they 
may be present in family members who are unaffected by autism, thus the 
causative effect is difficult to determine (Rutter). Surprisingly, many CNVs seem 
to be different in different families (Pinto et al., 2010). A number of single-gene 
disorders have been extensively studied and are used as ASD models, 
prominently including Fragile X, Rett and Timothy syndromes.  
Fragile X syndrome (FXS) is the leading cause of both inherited MR and 
ASD (Heulens and Kooy, 2011). It is caused by expansion of a CGG trinucleotide 
repeat in the promoter region of the FMR1 gene leading to hypermethylation and 
subsequent gene silencing (Verkerk et al., 1991). ~30% of Fragile X patients 
have autism co-morbidity (Bailey et al., 2008; Hagerman et al., 1986). Rett 
syndrome is one of the original DSM-designated pervasive developmental 
disorders, and the only one for which there is specific genetic etiology (Amir et 
al., 1999). Approximately 96% of Rett syndrome patients have mutations in the 
X-lined MECP2 gene. Children often have a period of normal development 
followed by loss of language with stereotypic hand movements (Miles, 2011). 
Timothy syndrome is an autosomal dominant disorder caused by a mutation in 
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the CACNA1C calcium channel gene at 12p13.3, and is characterized by cardiac 
defects as well as autistic symptoms (Splawski et al., 2004).  
 
Synaptic Mechanisms Underlying Disease States 
 At the junction between two neurons is a small gap, about 20 nm wide, 
which serves as a contact barrier between nerve cells. This physical gap, termed 
a “synapse”, is the site of communication from one neuron to another through 
secreted chemical signals, termed neurotransmitters. Synapse formation 
(synaptogenesis) is a critical stage in neural circuit assembly and synapse 
elimination (pruning) is a critical stage in neural circuit refinement. Synapses 
undergo both short- and long-lasting changes in structure/function (synaptic 
plasticity) that are critical for learning and memory (Steward and Schuman, 
2001). Defects in synaptogenesis and synaptic plasticity are considered to be the 
leading causes of MR and autism (Costa-Mattioli et al., 2009). The role of 
synapses in these developmental brain disorders has been studied extensively in 
FXS (absence of FMRP; neurons develop abnormally long and immature 
dendritic spines; impaired functional plasticity) (Dolen et al., 2007), Rett 
syndrome (excess MeCP2 leads to excess synapses) (Chao et al., 2007) and 
tuberous sclerosis (mutated TSC1/2 leads to excessive protein that alters 
synaptic cell signaling) (Ehninger et al., 2008). In ASD, mutations within the 
neuroligin gene family are associated with impaired synaptogenesis (Jamain et 
al., 2003).  
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 One important aspect of synapse biology is local protein translation, with 
developmental signals, electrical activity and behavioral experience all inducing 
synthesis of specific proteins necessary for enduring synaptic modifications 
(Steward and Schuman, 2001). Proteins that are newly synthesized must be 
made from mRNAs that are synthesized as a consequence of new transcriptional 
activation or from mRNAs that are constitutively present (local translation 
control). For the former, signaling must occur from the distant synapse to the 
neuronal nucleus transcriptional machinery and back again (Steward and 
Schuman, 2001), a very challenging proposition. For the latter, there must be a 
mechanism for regulating translation locally via synaptic activity, which includes 
maintained repression of translation until the activity-dependent trigger occurs. 
Studies using protein synthesis inhibitors have revealed that transient periods of 
synaptic development/pruning, long-lasting forms of synaptic plasticity and 
behavioral regulation all require tight control of protein synthesis (Bailey et al., 
1996; Davis and Squire, 1984; Schuman, 1999). 
 Synaptic plasticity, defined as alterations in the efficacy of synaptic 
transmission, has long been proposed to be the cellular basis for learning and 
memory (Bredt and Nicoll, 2003). Persistent changes in synaptic efficacy involve 
at least two phases; 1) an early phase (<1 hour) that is independent of new 
protein synthesis, and 2) a long-lasting late phase (hours to years) that is 
dependent on new protein synthesis (Richter and Klann, 2009). Long-term 
potentiation (LTP) and depression (LTD) refer to persistent increases or 
decreases in synaptic strength, respectively (Kandel, 2001). Most of the work on 
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LTP and LTD has been conducted in the hippocampus – the brain structure 
required for spatial memory consolidation (Richter and Klann, 2009). Ribosomes, 
translation factors and mRNA are present not only in neuronal cell bodies, but 
also in dendrites, dendritic spines, axonal growth cones and (debatably) mature 
axons, suggesting that local protein synthesis could aid in long-lasting synaptic 
plasticity and thus long-term behavior modifications without engaging 
transcriptional machinery (Steward and Schuman, 2001). Inhibition of translation 
initiation results in the abrogation of late LTP earlier than when transcription is 
inhibited, as induced by application of protein synthesis inhibitors (Banko et al., 
2005; Bradshaw et al., 2003). These data suggest that local protein synthesis is 
a critically important component of multiple forms of long-lasting hippocampal 
synaptic plasticity. 
 Spatial control of translation is an important task that neurons must be 
able to accomplish due to their inherent architectural complexity and network of 
disperse synaptic connections (Darnell, 2011). Synapses must be able to locally 
alter and regulate their ‘strength’ in response to local cues using mechanisms of 
new protein synthesis. In order to locally regulate protein synthesis, mRNAs must 
be transported to the neuronal processes, and be translationally repressed 
during transport localization (Darnell, 2011; Martin and Ephrussi, 2009) (Fig. 3). It 
is thought that such mRNAs are recognized through cis-acting RNA elements, 
which are mainly found in untranslated regions (UTRs), primarily in the 3-UTR 
(Andreassi and Riccio, 2009). These elements are variable in length and 
sequence and fold into distinct secondary structures that work as recognition 
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Figure 3. Translational regulation in neurons. While the soma was originally 
believed to be the site of all protein synthesis in the neuron (a) it is now clear that 
actively translating polyribosomes are present in and near the dendritic spines 
(the sites of postsynaptic excitatory input), (b), in growth cones during 
development and regeneration after injury (c) and arguably on the presynaptic 
side of synapses (d). Localized protein synthesis permits rapid changes in the 
local proteome but requires delivery of mRNA (black spirals) and synthetic 
machinery to the distant sites in the form of transport granules, with or without 
ribosomes (40S and 60S subunits are blue and red dots, respectively). The 
prevailing theory is that specific mRNA-binding proteins (light blue ovals) repress 
translation during transport (1) and maintain the mRNA in a repressed state until 
new protein synthesis is needed (2). Mechanisms exist to activate the synthesis 
of specific proteins in the dendrites and growth cones (3), and specific 
mechanisms halt their translation as well (4). Adapted from (Darnell, 2011). 
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platforms for trans-acting RNA-binding proteins. Among the best-studied RNA-
binding proteins is ZBP1, which binds the 3-UTR of -actin mRNA to drive its 
localization to axonal growth cones and dendrites (Zhang et al., 2001a). Other 
RNA-binding proteins with similar functions include Staufen (Mikl et al., 2011) 
and Fragile X Mental Retardation Protein (FMRP) (Zhang et al., 2001b). 
Following delivery to dendrites or axons, mRNAs are thought to be maintained in 
a repressed state until synaptic stimulation triggers activation of translation 
(Darnell, 2011). Translational regulatory initiation and elongation factors are 
regulated by phosphorylation, sequence-specific RNA binding proteins 
(RNABPs), and small non-coding RNAs (such as miRNAs) that regulate 
translation of a specific subset of mRNAs (Darnell, 2011).  
The two primary pathways for signal transduction from neuronal receptors 
to these translation regulatory factors are the PI3K/Akt/mTOR and MAPK/ERK 
kinase cascades (Costa-Mattioli et al., 2009; English and Sweatt, 1997; Hoeffer 
and Klann, 2010; Lin et al., 2001). Both pathways affect initiation by 
phosphorylation of translation factor eIF4E binding proteins (4EBPs), causing 
their release from eIF4E to increase initiation. Inhibition of translation initiation 
can result from stimuli that cause eIF2phosphorylation through kinase 
activation. Inhibition can also occur through the elongation phase, for example 
through synaptic glutamate receptor activation leading to eEF2 phosphorylation 
(Sutton et al., 2007). In addition to this critical translation control, remodeling of 
the synaptic environment can also be accomplished by the regulated degradation 
of proteins (Cajigas et al., 2010). Selective protein degradation provides a 
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mechanism to relieve inhibition and promote synaptic strengthening. Several 
reports have highlighted functions for the ubiquitin proteasome system (UPS) in 
synaptic development and plasticity (Haas and Broadie, 2008; Patrick, 2006; 
Patrick et al., 2003). The UPS attaches ubiquitin to lysine residues of specific 
protein substrates, which then triggers subsequent degradation of the 
ubiquitinated protein by the 26S proteasome. Thus, protein synthesis and 
degradation together provide a mechanism for fine-tuning protein availability 
locally in synapses, and this, in turn, leads to regulation of synaptic development 
and plasticity.  
 
Fragile X Syndrome 
 In 1943, Martin and Bell first described a new form of X-linked MR, and 
two decades later, Lubs in 1969 chanced upon a chromosomal test identifying a 
fragile site on the X chromosome (Lubs, 1969). More than two decades after that, 
in 1991, the disease-causing FMR1 gene was identified (Verkerk et al., 1991), 
followed quickly thereafter by a mouse model of the FXS disease (Bakker et al., 
1994). Not long afterwards, in 2000, the Drosophila homolog to FMR1 (dFMR1) 
was identified (Wan et al., 2000) and a fruit fly disease model generated by the 
Broadie Lab (Zhang et al., 2001b). FXS was initially described as non-syndromic 
but is now considered the most common type of syndromic XLMR (Ropers, 
2006). FXS is a wide spectrum neurological disorder, and the most common 
inherited cause of MR and ASD (Hagerman, 2008). The prevalence for the 
population as a whole is ~1:5000 (Coffee et al., 2009). Approximately 33% of 
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FXS patients are co-morbid for ASD, while ~2-3% of autistic patients have co-
morbidity with FXS (Rogers et al., 2001). Apart from the cognitive deficit 
hallmark, typical facial features such as an elongated face, protruding jaw line 
and enlarged ears characterize the syndrome. Elevation of birth weight in 
newborns, as well as macrocephaly in males commonly occur (Terracciano et al., 
2005). These non-neurological signs testify that the FMRP also functions in non-
neuronal tissues. The range of behavioral symptoms includes hyperactivity, 
obsessive-compulsive behaviors, sleep disorders, anxiety, and aggressive 
behavior (Chonchaiya et al., 2009). In about 20% of patients, epileptic seizures 
occur; however, typically decreasing with age (Musumeci et al., 1999). Mild to 
severe MR is the major phenotype of FXS. IQ in affected males ranges from 20-
60, but MR symptoms in females tend to be milder (Terracciano et al., 2005; 
Visootsak et al., 2005). Post-mortem neuropathological studies have shown 
longer, immature postsynaptic dendritic spines in both temporal and visual 
cortical areas (Irwin et al., 2001). Compared with the normal mushroom-shaped 
mature dendritic spines, FXS patients display more elongated dendritic spines as 
well as increased spine density (Irwin et al., 2000). Multiple neural circuits must 
be impacted in order to contribute to the spectrum of FXS disease symptoms.  
 
The Fragile X Mental Retardation 1 (FMR1) Gene 
 FXS normally arises as a consequence of a large expansion of a CGG 
trinucleotide repeat in the 5 untranslated region of the FMR1 gene (Oberle et al., 
1991). In the general population, normal individuals carry a polymorphic CGG 
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triplet ranging from 5-54 (mean=30) repeats upstream of the FMR1 gene. The 
abnormally high repeats (>200) in FXS patients lead to genomic 
hypermethylation and subsequent transcriptional silencing of the FMR1 gene 
(Fig. 4). At the cytogenetic level, the expansion can be seen as a gap/break on 
the X chromosome at Xq27.3 (the “FRAXA site”) when fragile X cells are grown 
under folate-depleted conditions (Sutherland, 1977). Intermediate numbers of 
CGG repeats (50-200), referred to as the ‘premutation condition’, occur in 
disease carriers who are asymptomatic in regards to FXS, but can show at low 
frequency an unassociated late-onset ataxia (Hagerman and Hagerman, 2002). 
Transmission of premutated alleles to the next generation may result in changes 
in the number of repeats, either decreasing or increasing. In the case of 
transmission by the mother, an expansion to full mutation will occur in ~80% of 
the cases when the premutation repeat number is between 50-110 (Heitz et al., 
1992; Yu et al., 1992). Repeat expansion from a premutation to a full-sized 
syndrome-causing mutation (>200) occurs in all tissues except the male germline 
(Bardoni et al., 2000). The rate of expansion into a full mutation depends on the 
size of the premutation; the smaller the premutation, the lower the chance of 
expansion. Males with the full mutation are always affected, whereas females 
carrying the mutation vary in phenotypic outcomes due to X-linked inactivation 
causing mosaicism (Wohrle and Steinbach, 1991). Male premutation carriers can 
develop a late-onset neurodegenerative syndrome called fragile X tremor/ataxia 
syndrome (FXTAS) (Hagerman et al., 2001). Conversely, female premutation 
carriers can develop fragile X-associated primary ovarian insufficiency (FXPOI)   
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Figure 4. FMR1 gene and its product. (Top) FMRP protein domains (green) 
and key residues (red). NLS, nuclear localization signal; KH1 and KH2, RNA-
binding domains; NES, nuclear export signal; RGG, RGG box, RNA-binding 
domain. I304N is a naturally occurring FXS mutation abrogating polysome 
association; murine S499 is the primary phosphorylated serine. (Middle) FMR1 
gene, coding exons (blue) and untranslated regions (gray). Exons coding for 
major protein domains are indicated, as well as alternative splicing. (Bottom) 5′ 
untranslated CGG-repeat alleles. The common and intermediate normal alleles 
(<55 repeats) are indicated, as are the premutation carrier alleles (55–200 
repeats) and the full-mutation FXS alleles (>200 repeats). Adapted from (Bassell 
and Warren, 2008). 
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(Vianna-Morgante et al., 1996). Only a few cases of sporadic FXS, without the 
CGG repeat expansion, have been reported (de Vries et al., 1998). In all these 
cases, either deletion within or around the FMR1 locus, or missense point 
mutations in the FMR1 coding sequence, confirm a causative role for loss of the 
FMR1 gene in FXS. Available treatments inadequately target only a subset of 
disease symptoms, so there is a pressing need for research into the genetic and 
neurobiological basis of this disease.  
 
Fragile X Mental Retardation Protein (FMRP) 
 FMRP appears fairly ubiquitously expressed in all tissues, albeit with 
particularly high expression in neurons (Verheij et al., 1993). The gene spans 
~40 kb and encodes a full length mRNA of 3.9 kb. The gene is composed of 17 
exons and its transcript is subjected to extensive alternative splicing (Ashley et 
al., 1993) (Fig. 4). FMR1 gene expression has been studied by in situ RNA 
hybridization in a variety of human and murine tissues. Widespread and strong 
expression was observed in early mouse embryos, while in successive stages of 
development, the levels of expression diminished and became more localized in 
tissues (Bakker et al., 1994). FMRP can be up to 632 amino acids long and has 
five defined functional domains: three types of RNA-binding domains (Siomi et 
al., 1993; Zanotti et al., 2006), namely two K Homology (KH) domains in the 
middle region of the protein (KH1, KH2; KH=heterogeneous nuclear 
ribonucleoprotein K homology) and an RGG box in the C-terminal region 
(containing repeats of an Arg-Gly-Gly motif); a non-classical nuclear localization 
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signal (NLS); and a nuclear export signal (NES) (Eberhart et al., 1996). FMRP 
also has two predicted coiled-coil domains important for protein-protein 
interactions.  
Only three pathological point mutations have been reported in the FMR1 
gene. An I304N missense mutation affecting the KH2 RNA binding domain was 
found in a single patient with unusually severe FXS symptoms (De Boulle et al., 
1993). KH domain functions in other proteins range from mRNA splicing to 
mRNA localization to translational control.  It was suggested that this mutation 
might cause a dominant negative effect, by affecting the structure of the 
messenger ribonucleoprotein (mRNP) complexes containing FMRP (Darnell et 
al., 2005). Two truncating mutations resulting in absence of FMRP were detected 
in another study (Coffee et al., 2008). The RGG box binds a G-quartet structure 
present in many FMRP mRNA targets (Darnell et al., 2001). In other proteins, 
RGG boxes have been shown to mediate RNP formation. FMRP also binds non-
coding adaptor RNAs, microRNAs and components of the RNA-induced silencing 
complex (RISC) (Jin et al., 2004; Zalfa et al., 2005). In the brain, FMRP mRNP 
complexes associate in an mRNA-dependent manner with actively translating 
polyribosomes (Khandjian et al., 1996; Tamanini et al., 1996), where FMRP acts 
as a negative translational regulator of target mRNAs (Laggerbauer et al., 2001; 
Sung et al., 2003). In mouse microarray screens, immunoprecipitated FMRP 
associates with ~4% of total brain mRNAs (Darnell et al., 2001), although there is 
growing evidence that this number is likely a gross exaggeration of the number of 
in vivo targets. Recent work to define FMRP RNA targets has been conducted 
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using high-throughput sequencing of RNAs isolated by crosslinking 
immunoprecipitation (HITS-CLIP) from the mouse brain (Darnell et al., 2011). 
The brain polyribosome-programmed translation system developed in this study 
reveals that FMRP reversibly stalls ribosomes during translation elongation of 
target mRNAs. The results suggest that loss of the FMRP translational “brake” on 
the synthesis of a subset of synaptic proteins is the causative defect in FXS 
(Darnell et al., 2011). Overlap between the FMRP targets identified and the 
current list of autism susceptibility genes and loci sheds light on common 
pathways between the two disease states, supporting the hypothesis that 
synaptic dysfunction is critical to the development of autistic features common to 
FXS and ASD (Kelleher and Bear, 2008).  
 FMRP has been predicted to shuttle between the nucleus and cytoplasm. 
However, conventional methods do not usually show any detectable FMRP in the 
nucleus, although faint nuclear localization has been reported using both light 
and electron microscopy (Feng et al., 1997; Verheij et al., 1993). These reports 
conclude that <5% of the total FMRP is localized in the nucleus under normal 
conditions. Cells that have been treated with leptomycin B, which blocks mRNA 
export, reportedly weakly retain FMRP in the nucleoplasm; however, in all cases, 
the vast majority of FMRP protein is still localized in the cytoplasm (Tamanini et 
al., 1999). Supporting nuclear localization, FMRP reportedly interacts with a 
distinct set of nuclear proteins including nucleolin and the nuclear FMRP-
interacting protein (NUFIP) (Bardoni et al., 1999). In the nucleus, one role of 
FMRP could be to associate with target mRNAs and escort them out of the 
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nucleus (Eberhart et al., 1996). A mutated form of FMRP, I304N in the KH2 
domain, reportedly shuttles more frequently between the nucleus and the 
cytoplasm, which may indicate either that many domains are involved in nuclear 
import and export, or that bound mRNA slows the transport/shuttling process or 
makes re-entry into the nucleus more difficult (Tamanini et al., 1999). A second 
possible role for FMRP in the nucleus could be chromatin remodeling. In vitro, 
FMRP strongly binds single-stranded DNA (Dejgaard and Leffers, 1996). 
Mammalian FMRP has been shown to interact with a mammalian Argonaute 
protein (eIF2C2), and three components bound together (FMRP, Argonaute, and 
miRNAs) have also been detected where RNAi-mediated pathways operate 
(Matzke and Birchler, 2005).  
 Translation in neurons involves the transport of some mRNAs away from 
the cell body and local protein synthesis in dendrites and possibly axons 
(Steward and Schuman, 2003). Several lines of evidence suggest that FMRP has 
an active role in this mRNA transport, although there is no direct evidence that it 
is required for the transport process per se. FMRP and its mRNA are found in 
both the cell body and, at a much lower level, bound in a detectable granule in 
dendritic processes, including dendritic spines. In dendrites and spines, FMRP 
and FMR1 target mRNA co-localize in large, mobile granules (Zalfa et al., 2006), 
and the movement of these granules into dendrites is enhanced by neuronal 
signaling through metabotropic glutamate receptors (mGluRs). One target of 
FMR1 regulation is its own message, forming an activity-regulated negative 
feedback loop (Bagni and Greenough, 2005). FMRP is translated in unstimulated 
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synaptoneurosomes (a synaptic fraction containing pre- and postsynaptic termini; 
the presynaptic compartment contains the synaptic vesicles and the postsynaptic 
compartment contains the translational machinery) as well as in response to 
mGluR stimulation (Weiler et al., 1997). It is feasible to hypothesize that FMRP is 
translated locally at the synapse and not during the transport process. In the end, 
both FMR1 message and FMRP are transported in granules to locations 
throughout the dendrite, where translation of mRNA is regulated by synaptic 
activation. In the absence of FMRP, mGluR activation does not trigger increased 
protein synthesis in synaptoneurosomes (Weiler et al., 1997).  
 Using immunoprecipitation, two-hybrid screens and mass spectrometry 
analysis, several groups have identified proteins that interact with FMRP (Darnell 
et al., 2005; Darnell et al., 2011; Reeve et al., 2008). A few examples of these 
interactors include nucleolin, 82-FIP, RanBPM, Dicer, FXR1P/2P, and 
eIF2C2/AGO1. Most of the interacting proteins bind with the amino terminal 
portion of FMRP. The only protein that has been found to interact with the FMRP 
C terminus is RanBPM (Menon et al., 2004; Nakamura et al., 1998). The 82 kDa 
FMRP-interacting protein (82-FIP) is found in both the nucleus and cytoplasm 
(Bardoni et al., 2003). It shows no homology to proteins of known function, and 
contains no defined functional domains. It is found in most neurons and its 
subcellular distribution is cell-cycle dependent in COS cells, indicating that the 
composition of some FMRP-containing mRNP complexes might be cell cycle 
modulated. Interestingly, none of the proteins that interact with FMRP have yet to 
be associated with a disease state, and none of the genes that encode FMRP-
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interacting proteins have, so far, been linked to hereditary MR. FMRP binds to 
RNA homopolymers and to a subset of transcripts found in the brain (Brown et 
al., 2001; Chen et al., 2003; Zalfa et al., 2003). Four mechanisms of RNA target 
recognition have been suggested: i) recognition of G-quartet secondary RNA 
structure (Darnell et al., 2001), or ii) a poly (U) stretch in the mRNA (Brown et al., 
1998); iii) FMRP binding indirectly to the mRNA through either a small non-
coding RNA brain cytoplasmic RNA 1 (BC1) (Iacoangeli et al., 2008) or iv) 
through miRNAs (Edbauer et al., 2010). BC1 RNA is predicted to base pair to 
neuronal mRNAs that encode molecules that are important for synaptic structure 
and function, such as MAP1B (microtubule associated protein 1B) mRNA 
(Iacoangeli et al., 2008). It has been shown that human FMRP associates with 
miRNAs, which inhibit mRNA expression (Duan and Jin, 2006). FMRP could 
contribute to this regulatory pathway by stabilizing the specific annealing 
between miRNAs and the complementary region in the 3 untranslated region of 
the target mRNAs. The learning and memory difficulties that are found in patients 
with FXS are widely attributed to alterations in mRNA metabolism regulating 
synapse structure and function.  
 
Translational Control by Fragile X Mental Retardation Protein 
 FMRP is an RNA-binding protein that associates with many mRNAs 
encoding proteins important for synaptic development and plasticity (Darnell et 
al., 2001). FMRP controls dendritic mRNA localization (Dictenberg et al., 2008), 
stability (D'Hulst et al., 2006) and translational efficiency of dendritic mRNAs in 
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response to stimulation of mGluRs (group 1 metabotropic glutamate receptor) 
(Napoli et al., 2008), and likely other cell surface receptors. In neurons, FMRP is 
packaged into messenger ribonucleoprotein (mRNP) particles that contain 
several other proteins involved in translation control (Staufen, eIF4E, ribosomal 
proteins), as well as cytoskeleton dynamics (tubulin, Rac1, CYFIP) and motor 
transport (dynein, kinesins) (Brendel et al., 2004; Kanai et al., 2004; Napoli et al., 
2008). The range of FMRP regulatory targets is famously uncertain, however 
some consensus targets have emerged in recent years. CaMKII 
(Ca2+/calmodulin-dependent protein kinase and Arc (activity-regulated 
cytoskeleton-associated protein) are proposed FMRP translation regulatory 
targets, synthesized de novo in response to neuronal activity and critical for 
synaptic plasticity (Kanai et al., 2004; Kao et al., 2010; Krueger et al., 2011; Park 
et al., 2008).  
The molecular mechanism by which FMRP controls translation has been 
investigated by assessing the polysome/mRNP distribution of the FMRP-
containing complex (Ceman et al., 2003). FMRP has been shown to co-sediment 
with polyribosomes (Stefani et al., 2004), and its phosphorylation state is a 
critical determinant of polyribosome association (Ceman et al., 2003). FMRP has 
also been shown to co-sediment equally between polyribosomes and non-
translating mRNP fractions (Brown et al., 2001). Yet other findings suggest that 
FMRP primarily associates with the mRNP fraction (Napoli et al., 2008; Zalfa et 
al., 2003), perhaps indicating repression at the initiation step. FMRP may inhibit 
translation at initiation through an interacting factor, CYFIP1 (cytoplasmic FMRP-
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interacting protein 1) (Napoli et al., 2008), which associates the cap-binding 
factor eIF in mRNP fractions. The same study also suggested that CYFIP1 is 
important in the FMRP-regulatory circuit: an increased level of proteins encoded 
by known FMRP target mRNAs was seen upon reduction of CYFIP1 in neurons. 
An alternative model for how FMRP represses translation suggests that CYFIP1 
would be tethered to FMRP as well as to eIF4E (Napoli et al., 2008). By binding 
eIF4E, CYFIP1 would exclude eIF4G and, indirectly, the 40S ribosomal subunit 
from associating with mRNA. In this model, a synaptic activity trigger would 
release CYFIP1 from eIF4E to allow translation initiation (Napoli et al., 2008). 
Another FMRP binding partner, brain cytoplasmic RNA 1 (BC1), a non-coding 
RNA, increases the affinity of FMRP for the CYFIP1-eIF4E complex in brain 
(Napoli et al., 2008). It has been clearly demonstrated that FMRP negatively 
regulates translation both in the mouse and in the Drosophila models of FXS 
(Coffee et al., 2010; Qin et al., 2005).  
 
Genetic Models of Fragile X Syndrome 
 There are two well-established animal models of FXS: in the mouse and 
the fruit fly. The FMR1 knockout (KO) mouse (Bakker et al., 1994) was reported 
first in 1994, while the Drosophila KO model was reported in 2001 (Zhang et al., 
2001b). The mouse FMR1 KO model displays relatively very mild 
learning/memory impairments, but better recapitulates other FXS behavioral 
symptoms including hyperactivity and seizures in response to audiogenic stimuli 
(Qin et al., 2011). Neither FXS patients nor FMR1 KO mice have gross brain 
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defects; however, individual neuronal structure displays aberrant dendritic 
structural phenotypes, e.g. expanded dendritic arbors and immature dendritic 
spines in both patients and model (Hinton et al., 1991). In normal development, 
an overproduction of spines is followed by a period of activity-dependent pruning. 
One possibility is that FMR1 KO mice fail to normally prune these synaptic 
processes. Such defects in dendritic spine pruning vs. maturation may indicate 
that FMRP regulates experience-dependent synaptogenesis and synapse 
stabilization (Braun and Segal, 2000; McKinney et al., 2005). While basal 
synaptic function appears relatively normal in mutant mice, hippocampal long-
term depression (LTD) dependent on activation of mGluRs is selectively 
enhanced (Bear et al., 2004). LTD is one of the mechanisms that contribute to 
learning and memory in the brain by triggering long lasting synaptic 
modifications, especially activity-guided synapse elimination (Costa-Mattioli et al., 
2009). Mouse studies also show a clear role for FMRP in the axonal growth 
cone, presynaptic terminal and in presynaptic signaling (Christie et al., 2009; 
Deng et al., 2011). Mouse FMR1 KO brains have reduced overall levels of mRNA 
granules, interpreted as a reduced number of translationally silent polyribosomes 
(Aschrafi et al., 2005).  
 A CGG trinucleotide repeat mouse has also been generated in an attempt 
to better understand the timing and mechanism involved in the FMR1 CGG 
repeat instability, expansion and methylation state (Bontekoe et al., 2001). The 
endogenous repeat was replaced with a human CGG repeat carrying 98 units. 
Showing mild instability upon maternal transmission, the length has since been 
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expanded to 230 repeats. Disappointedly, methylation of the CpG islands still 
remains absent even though the repeat number is >200, as in the full mutation 
human disease condition (Bontekoe et al., 2001). This mouse model does not 
exhibit FXS phenotypes, but rather FXTAS, with levels of mRNA elevated and 
FMRP levels decreased, just as in the FXTAS premutation condition (Brouwer et 
al., 2008; Brouwer et al., 2007). Therefore, either more repeats or other genetic 
manipulation are necessary in order to model FXS with a CGG full mutation 
expansion in mouse. One very recent body of work investigates the effects of 
FMRP ablation in adult neural stem cells and demonstrates the disruption of 
hippocampus-dependent learning (Guo et al., 2011). This work investigated the 
function of FMRP expression in neural stem and progenitor cells and its role in 
adult neurogenesis (Deng et al., 2010b). Removal of FMRP in these cells by 
inducible gene recombination leads to reduced hippocampal neurogenesis in 
vitro and in vivo, as well as impaired hippocampal-dependent learning in mice. 
Restoration of FMRP expression specifically in these neural stem cells rescues 
learning defects in FMRP-deficient mice. Therefore, this work suggests that adult 
neurogenesis may contribute to the learning impairment seen in FXS, and these 
learning deficits can be corrected by delayed restoration of FMRP specifically in 
the neural stem and progenitor cells (Guo et al., 2011).  
 The Drosophila FXS model was established by an imprecise P-element 
excision to produce a series of dfmr1 null mutants (Zhang et al., 2001b). Since 
then, an array of additional dfmr1 alleles and transgenes has been created to 
facilitate FXS research in this model (Lee et al., 2003; Morales et al., 2002). 
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Drosophila FMRP (dFMRP) displays close homology with mammalian FMRP, 
including conserved structure, RNA-binding properties, tissue and subcellular 
expression patterns, and a conserved functional role as a negative translational 
regulator (Wan et al., 2000; Zhang et al., 2001b) (Fig. 5). Importantly, however, 
the Drosophila genome contains only a single FMR1 gene, whereas vertebrate 
genomes contain three highly related genes: FMR1 and two associated paralogs 
(Fragile X-related genes 1 and 2; FXR1, FXR2). dFMRP may regulate translation 
via the miRNA pathway:  dFMRP associates with the RISC complex (Caudy et 
al., 2002; Ishizuka et al., 2002), and dfmr1 mutants interact genetically with the 
RISC pathway (Jin et al., 2004), which modulates synaptic protein synthesis 
required for memory formation in Drosophila (Ashraf et al., 2006). Null dfmr1 
mutants exhibit reduced motor coordination (Xu et al., 2004; Zhang et al., 
2001b), irregular circadian activity levels (Dockendorff et al., 2002; Inoue et al., 
2002), and defective learning and memory (Bolduc et al., 2008; Dockendorff et 
al., 2002). Male dfmr1 flies also display enlarged testes, and spermatogenesis 
and fecundity defects (Coffee et al., 2010; Zhang et al., 2004), while females 
display oogenesis defects (Costa et al., 2005), as in the human disease state. 
dFMRP is a negative regulator of growth, branching and synaptic differentiation 
in many neural circuits including motoneurons at the neuromuscular junction 
(NMJ) (Coffee et al., 2010; Gatto and Broadie, 2008; Zhang et al., 2001b), 
peripheral sensory neurons (Lee et al., 2003) and multiple classes of central 
brain interneurons (Michel et al., 2004). In the mushroom body (MB) learning and 
memory brain center, individual Kenyon Cell neurons display over-elaborated   
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Figure 5. Protein domain comparisons. Drosophila FMRP (dFMRP; top) 
shares functional domain conservation and a high level of homology with human 
FMRP (hFMRP; bottom). Overall there is 56% peptide similarity. dFMRP is 681 
amino acids in length while hFMRP is 632 amino acids in length. 
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axonal and dendritic structural development (Michel et al., 2004). In addition, 
circadian activity is controlled by the well-defined clock circuitry, in which the 
small ventrolateral (sLNv) neurons are sufficient for pacemaker activity (Grima et 
al., 2004). In these cells, null dfmr1 mutants display an over-elaborated synaptic 
bouton array that extends well beyond the normal termination points (Coffee et 
al., 2010; Gatto and Broadie, 2009). 
Molecular mechanisms of dFMRP function have been dissected by 
dFMRP immunoprecipitation and genetic interaction studies (Broadie and Pan, 
2005). To date, dFMRP is known to regulate six mRNAs: i) futsch, encoding 
MAP1B, which regulates microtubule dynamics (Zhang et al., 2001b). Genetic 
studies demonstrate that misregulation of futsch translation is a primary cause of 
synaptic structure-function defects in dFMR1 mutants. ii) Rac1 (Ras-related C3 
botulinum toxin substrate); genetic evidence suggests that dFMRP down-
regulates Rac1 translation. Through regulation of Rac1 and cytoplasmic FMRP 
interacting protein (CYFIP/Sra-1), dFMRP plays a key role in modulating the 
actin cytoskeleton during neuronal morphogenesis (Schenck et al., 2003). iii) 
chickadee, encoding actin-binding profilin (Reeve et al., 2005). Profilin regulates 
actin dynamics/stability and its misregulation in dfmr1 mutants is a primary cause 
for structural defects (Tessier and Broadie, 2008). iv) pickpocket1, encoding a 
Degenerin/Epithelial Sodium Channel (DEG/ENaC) subunit; genetic evidence 
suggests dFMRP represses Pickpocket1 expression in an argonaute1-dependent 
mechanism, confirming a role in the miRNA pathway (Xu et al., 2004). More 
recently, work from our laboratory has shown that dFMRP regulates mRNA 
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expression of several calcium-binding proteins, including Frequenin 1/2, 
Calmodulin and Calbindin (Tessier and Broadie, 2011). Taken together, these 
RNA targets strongly suggest that actin/microtubule cytoskeleton regulation, in 
addition to calcium signaling regulation, are primary components of dFMRP 
function mediating synaptic processes.  
 
Molecular Pathways Involved in Fragile X Syndrome 
 Huber and Bear famously first reported that hippocampal postsynaptic 
group 1 class 5 metabotropic glutamate receptor (mGluR)-mediated LTD, a 
specific form of protein synthesis-dependent synaptic plasticity, is elevated in 
Fmr1 KO mice (Huber et al., 2002). LTP remains normal in the hippocampus, but 
defective in the neocortex (Wilson and Cox, 2007). mGluR-LTD requires rapid 
translation of pre-existing mRNA and stimulates loss of surface expressed 
synaptic AMPA and NMDA receptors via recycling pathways. Activation of 
mGluR5 also regulates trafficking of AMPA GluRs (Nosyreva and Huber, 2005). 
Thus, the mGluR theory of FXS states that dysregulated mGluR5 centrally 
contributes to the pathology of FXS (Bear et al., 2004). The theory further 
suggests that mGluR activation normally stimulates synthesis of proteins 
involved in stabilization of LTD, and FMRP functions as a negative translational 
regulator that puts a brake on LTD.  
It has also been proposed that the phosphorylation of FMRP on a specific 
serine residue switches the protein to an activated state (association with stalled 
polyribosomes) in which it can then proceed as a translational repressor (Ceman 
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et al., 2003). Subsequent release from stalled polyribosomes onto actively 
translating polyribosomes has been proposed to occur through a switch to the 
dephosphorylated state. Further reports demonstrate that dephosphorylation of 
FMRP leads to synapse loss through acute postsynaptic translational regulation 
(Pfeiffer and Huber, 2007). Induction of mGluR-LTD is proposed to be caused by 
an increase in synaptic stimulation as well as iontotropic glutamate receptor 
(GluA) endocytosis (Gladding et al., 2009). Reduced levels of FMRP lead to 
increased mGluR5-mediated GluA endocytosis in rat hippocampal neurons 
(Nakamoto et al., 2007). Treating Fmr1 KO mice with the mGluR5 antagonist, 
MPEP (blocks mGluR5 activity), can increase habituation in open field tests, 
decrease sensitivity to audiogenic seizures (Yan et al., 2005), and rescue 
courtship learning and memory defects in Drosophila (McBride et al., 2005). 
Work in Drosophila demonstrates that dFMRP protein expression is upregulated 
in DmGluRA mutants, removing the sole Drosophila mGluR (Pan et al., 2008). 
Conversely, DmGluRA is upregulated in dfmr1 mutants, demonstrating mutual 
negative feedback. This work further shows that DmGluRA nulls display defects 
in coordinated movement, which are rescued by the removal of dFMRP. Further, 
blocking of mGluR signaling alleviates the NMJ structural overgrowth and the 
elevation of presynaptic vesicle pools in the dfmr1 mutant (Pan et al., 2008). The 
data in this study suggest that DmGluRA and dFMRP convergently regulate 
neuronal presynaptic properties. Therefore, development of antagonistic drugs 
targeting mGluRs could prove to be a promising therapeutic strategy for the 
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treatment of FXS and is currently being investigated by pharmaceutical 
companies.  
 Another synapse class suggested to be dysregulated in FXS is the 
GABAergic inhibitory pathway (Centonze et al., 2007). Fmr1 KO mice show loss 
of GABAergic inhibition (Gross et al., 2011). Impaired GABAergic signaling in 
FXS might be caused by decreased expression of GABA receptors (D'Hulst et 
al., 2006). GABAAR subunit mRNA and protein levels are decreased in both 
mouse and Drosophila FXS models, thus suggesting that FMRP contributes to 
the stability and/or translation of GABAAR transcripts (D'Hulst et al., 2009; 
Gantois et al., 2006). GABA administration in the Drosophila FXS model blocks 
glutamate toxicity, and rescues Futsch over-expression, neuronal overgrowth 
defects and memory impairment (Chang et al., 2008), as well as neuronal hyper-
excitability (Olmos-Serrano et al., 2010). Impaired GABAergic signaling could 
also be the result of the dysregulation of mGluRs, as there is crosstalk between 
these two receptor types in several different brain regions (Deng et al., 2010a; 
Hirono et al., 2001). Targeted therapeutic treatments and development of 
agonistic drugs for GABARs are currently being generated and investigated.  
 
Hypothesis and Aims 
 The long-term goal of this thesis work was to better understand the 
molecular and synaptic mechanisms of behavioral dysfunction in the FXS 
disease state. The FMR1 gene was cloned 20 years ago, but the molecular and 
neurobiological basis of the disease remains surprisingly elusive. I have used the 
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established Drosophila FXS model to test the functional conservation between 
dFMR1 and its three human homologs. I have also conducted a structure-
function analysis of FMRP, targeting a well-conserved phosphorylation residue 
involved in regulation and signaling. This was the first study of FMRP protein 
domain requirements in vivo. My hypothesis is that FMRP shuttles to the nucleus 
where it binds specific mRNA targets via the synergistic interaction of multiple 
RNA-binding domains, then escorts these mRNAs to their final cellular 
destinations, and finally regulates their translation downstream of 
phosphorylation-dependent signaling event (Fig. 6). I further hypothesize that this 
mechanism has been evolutionarily conserved from Drosophila to man, albeit 
with evolutionarily derived, message-specific functions sub-served by the three-
member protein family in human.  
 The first aim of this work was to test the functional conservation of dFMR1 
and the human three-gene family (hFMR1/hFXR1/hFXR2) (Coffee et al., 2010). 
First, I show that human FMR1 replaces all Drosophila FMR1 functions just as 
well as the native gene, indicating complete functional conservation. Second, I 
show that FMR1 has a unique function in Drosophila neurons as a translational 
regulator sculpting synaptic connections, which cannot be compensated for by 
FXR1 or FXR2. Lastly, I show that the entire human gene family can fully replace 
each other’s function in the non-neuronal setting of the Drosophila testes, 
demonstrating a fundamentally different mechanistic requirement in non-neuronal 
cells that can be fulfilled by any of the three family members.   
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Figure 6. Model for FMRP function. FMRP enters the nucleus and could 
function through two possible mechanisms. In the first (1), FMRP could interact 
with other proteins, with itself (for example, the FMRP paralogs FXR1P and 
FXR2P), and with RNA/mRNA to form a ribonucleocomplex that may be involved 
in mRNA export from the nucleus to the cytoplasm. Once in the cytoplasm, a 
'core' complex, containing FMRP and some of its nuclear partners, would interact 
with cytoplasm-specific proteins (such as cytoplasmic FMRP-interacting protein 1 
(CYFIP1), CYFIP2 and Staufen) and move along processes to the synapses, 
transporting RNA/mRNA and, later, regulating synaptic protein synthesis. In the 
second mechanism (2), FMRP could be involved in the nuclear RNA interference 
pathway that is associated with small, non-coding RNAs (short hairpin RNAs or 
shRNAs) and specific nuclear partners (that is, nucleolin and Y-box binding 
protein 1 (YB1)). miRNA, microRNA; ncRNA, non-coding RNA. Adapted from 
(Bagni and Greenough, 2005). 
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 The second aim of this work was to test in vivo requirements of FMR1 
phosphorylation state of a specific serine residue. Here, I study the effects of the 
phosphorylation state of a serine residue (S500) previously reported to serve as 
a ‘switch’ from an activated (phospho-FMRP) to deactivated (dephospho-FMRP) 
state (Ceman et al., 2003; Narayanan et al., 2008). I used transgenic expression 
of a phospho- and dephosphomimetic (S500D-hFMR1 and S500A-hFMR1, 
respectively) in the dfmr1 null mutant background to test in vivo requirements. 
Prior in vitro work has shown that the mouse FMRP phosphorylation is necessary 
for the regulation of FMRP’s role as a negative translational regulator 
(Narayanan et al., 2008). My in vivo work here demonstrates that the S500D-
hFMR1 phosphomimetic can restore wildtype FMRP function, while the S500A-
hFMR1 dephosphomimetic is unable to restore function in all molecular, cellular 
and behavioral assays. I conclude that human FMRP S500 phosphorylation is 
necessary for its in vivo function as a neuronal translational repressor and 
regulator of synaptic architecture, and for the manifestation of FMRP-dependent 
learning behavior.  
 Taken together, my studies show that FMR1 function has been 
evolutionarily conserved from Drosophila to man, and that the human paralogs 
(FXR1 and FXR2), probably rising through a duplication event, are only able to 
compensate for lack of FMR1 in a non-neuronal tissue. Further, I demonstrate 
that S500 phosphorylation is critically important for FMRP function as the 
phosphomimetic, S500D-hFMR1, is able to phenocopy wildtype protein function, 
while the dephosphomimetic, S500A-hFMR1, is unable to provide any function 
 37 
and so resembles the null mutant condition. These studies provide strong 
evidence that the Drosophila FXS model is an extraordinarily beneficial system in 
which to study FXS and to gain insight into its causative molecular, cellular, and 
behavioral mechanisms of the disease state.  
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Abstract 
 Fragile X syndrome (FXS), resulting solely from loss of function of the 
human Fragile X Mental Retardation 1 (hFMR1) gene, is the most common 
heritable cause of mental retardation and autism disorders, with syndromic 
defects also in non-neuronal tissues. The human genome additionally encodes 
two closely related hFMR1 paralogs: hFXR1 and hFXR2.  The Drosophila 
genome, in contrast, encodes a single dFMR1 gene with similar close sequence 
homology to all three human genes. Null dfmr1 mutants recapitulate FXS-
associated molecular, cellular and behavioral phenotypes, suggesting FMR1 
function has been conserved, albeit with specific functions possibly sub-served 
by the expanded human gene family. To test evolutionary conservation, we used 
tissue-targeted transgenic expression of all three human genes in the Drosophila 
 39 
disease model to investigate function at 1) molecular, 2) neuronal and 3) non-
neuronal levels. In neurons, dfmr1-null mutants exhibit elevated protein levels 
altering central brain and neuromuscular junction (NMJ) synaptic architecture, 
including increased synapse area, branching, and bouton numbers. Importantly, 
hFMR1 can fully rescue both the molecular and cellular defects in neurons, 
comparably to dFMR1, whereas hFXR1 and hFXR2 provide absolutely no 
rescue. For non-neuronal requirements, we assayed male fecundity and testes 
function. Null dfmr1 mutants are effectively sterile due to disruption of the 9+2 
microtubule organization in the sperm tail. Importantly, all three human genes 
fully and equally rescue mutant fecundity and spermatogenesis defects. These 
results indicate that FMR1 gene function is evolutionarily conserved in neural 
mechanisms and cannot be compensated by either FXR1 or FXR2, but that all 
three proteins can substitute for each other in non-neuronal requirements. We 
conclude that FMR1 has a neural-specific function distinct from its paralogs, and 
that the unique FMR1 function is responsible for regulating neuronal protein 
expression and synaptic connectivity.  
 
Introduction 
 Fragile X syndrome (FXS) is the most common cause of inherited mental 
retardation and the leading known genetic cause of autism (Clifford et al., 2007; 
Cohen et al., 2005; Fisch et al., 2002; Hagerman et al., 2005; Rogers et al., 
2001). The X-chromosome linked disorder is caused by loss of a single gene 
function, fragile X mental retardation 1 (FMR1), most frequently by expansion of 
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CGG repeats (>200 repeats) in the 5 regulatory region causing hypermethylation 
that results in transcriptional silencing (Heitz et al., 1992; Oberle et al., 1991; 
Pieretti et al., 1991). In addition to mental impairment, FXS patients also display 
a wide range of social interaction problems characterized by poor eye contact, 
hyperactivity, attention deficit and obsessive-compulsive behaviors (Boccia and 
Roberts, 2000; Cornish et al., 2001; Fryns et al., 1984; Torrioli et al., 2008), and 
hypersensitivity to sensory stimuli (Fryns, 1984; Hessl et al., 2001). Other 
physical anomalies include elongated face, prominent ears and enlarged male 
testes (Chudley and Hagerman, 1987; Giangreco et al., 1996; Moore et al., 
1982). These non-neurological symptoms testify that the FMR1 gene performs 
important functions in non-neuronal tissues. Indeed, the FMR1 product (FMRP) 
is ubiquitously expressed, albeit with elevated expression in brain and testes 
(Agulhon et al., 1999; Devys et al., 1993). Although FXS is a monogenic disease, 
the wide range of clinical symptoms strongly indicates that FMRP is involved in 
the regulation of multiple modulatory factors. 
 FXS has been extensively investigated in both vertebrate and invertebrate 
genetic model systems (Bassell and Warren, 2008; Gatto and Broadie, 2009b). 
In all systems, FMRP has five well-defined functional domains: two RNA-binding 
KH domains in the middle region (KH1, KH2; KH = heterogeneous nuclear 
ribonucleoprotein K homology)(Siomi et al., 1993), an RNA-binding RGG box in 
the C-terminal region (containing repeats of an Arg-Gly-Gly motif) (Darnell et al., 
2001), a non-classical nuclear localization signal (NLS) and a nuclear export 
signal (NES) (Eberhart et al., 1996; Zhang and Broadie, 2005). Consistent with 
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its ability to bind RNA, FMRP regulates transcript trafficking and functions as a 
negative regulator of translation (Dictenberg et al., 2008; Estes et al., 2008; 
Laggerbauer et al., 2001; Mazroui et al., 2002). In vertebrates, FMRP is part of a 
3-member family that includes two other similar proteins: Fragile X-related 
protein 1 (FXR1P) and 2 (FXR2P). The autosomally-encoded paralogs express 
in a very similar tissue and cellular profile to FMRP, including the subcellular 
distribution in neurons, with only slight differences (Agulhon et al., 1999; Bakker 
et al., 2000). For example, FXR1P is more abundantly expressed in cardiac and 
skeletal muscle compared to FMRP and FXR2P (Bakker et al., 2000; Mientjes et 
al., 2004).  Moreover, all three proteins show ultrastructurally overlapping 
expression, can be co-immunoprecipitated and can associate with the same 
protein partners (Bakker et al., 2000; Ceman et al., 1999; Christie et al., 2009; 
Schenck et al., 2001; Zhang et al., 1995). Both hetero- and homo-dimerization of 
the FMRP/FXR1P/FXR2P family has been proposed to occur (Ceman et al., 
1999; Christie et al., 2009; Tamanini et al., 1999b; Zhang et al., 1995). 
 Only loss of FMR1 causes FXS, and loss of FXR1 or FXR2 has not been 
linked to any disease state. However, the mouse FXR1 knockout is lethal shortly 
after birth due to defects in cardiac and skeletal muscle development (Mientjes et 
al., 2004), whereas both FMR1 and FXR2 knockouts, as well as double 
knockouts, are adult viable. At least some FXS-like phenotypes are exhibited in 
FXR2 knockout mice (Bontekoe et al., 2002), while FMR1 knockouts recapitulate 
many FXS symptoms including learning defects, hyperactivity, sensory 
hypersensitivity, social deficits and macroorchidism (Chen and Toth, 2001; 
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Dobkin et al., 2000; McNaughton et al., 2008; Slegtenhorst-Eegdeman et al., 
1998). At a cellular level, FMR1 knockouts exhibit elevated brain protein 
synthesis levels (Qin et al., 2005) and accumulation of developmentally arrested 
postsynaptic spines (Comery et al., 1997; Nimchinsky et al., 2001).  Interestingly, 
double knockout of FMR1 and FXR2 results in augmented defects, including 
exaggerated behavioral phenotypes in open-field activity, prepulse inhibition of 
acoustic startle response, contextual fear conditioning and circadian arrhythmicity 
(Spencer et al., 2006; Zhang et al., 2008), and worsened cellular phenotypes, 
including further enhanced long-term depression (LTD) (Zhang et al., 2009). 
These data predict that the paralogs have overlapping functions and/or 
compensate for each other. However, expression levels of FXR1/2 are unaltered 
in FMR1 null mice and, similarly, levels of FMRP and FXR1P are unaltered in 
FXR2 null mice (Bakker et al., 2000; Bontekoe et al., 2002). Recent work has 
shown that kissing-complex RNA (kcRNA) interference with the KH2 domain is 
able to displace FXR1P and FXR2P from polyribosomes as it does for FMRP 
(Darnell et al., 2009); however, FMRP has a unique ability to recognize G-
quadruplexes, suggesting that the FMRP RGG box domain function may not be 
duplicated in the two paralogs. Thus, despite co-expression, co-molecular 
complex formation and phenotypic interactions between these three gene family 
members, evidence of their distinctive versus overlapping roles remains elusive. 
 The single Drosophila FMR1 gene (dFMR1) product is nearly identically 
homologous overall to all three human family members: 35% identity/56% 
similarity compared to hFMRP, 37% identity/65% similarity compared to hFXR1P 
 43 
and 36% identity/65% similarity compared to hFXR2P. The N-terminal region has 
a higher homology (dFMRP:hFMRP 50% identity, 84% similarity), with the C-
terminal being relatively divergent (Zhang et al., 2001). Importantly, dFMRP 
displays highly conserved structure in all defined functional domains: KH1, 68% 
identity; KH2, 67% identity; RGG box, 62% identity; NLS, 48% identity; NES, 
65% identity (compared to hFMRP). With the exception of FMR1 exons 11/12, for 
which there are no corresponding FXR1/2 sequences, exon 1-10 and 13 sizes 
are nearly identical in FMR1, FXR1 and FXR2 (Kirkpatrick et al., 2001). Non-
mammalian FMR1 orthologs similarly lack exons 11 and 12. These comparisons 
imply that the mammalian gene family likely arose by duplication from a common 
ancestor similar to the Drosophila FMR1 gene. Consistently, dFMRP displays 
conserved RNA-binding domains, tissue and subcellular expression patterns, 
and functional roles in mRNA trafficking and negative translational regulation 
(Banerjee et al., 2007; Epstein et al., 2009; Estes et al., 2008; Reeve et al., 2005; 
Zhang et al., 2001; Zhang et al., 2005). Moreover, dFMR1 knockout closely 
recapitulates FXS symptoms in a wide range of molecular, cellular, and 
behavioral phenotypes (Bolduc et al., 2008; Dockendorff et al., 2002; Gatto and 
Broadie, 2009a; McBride et al., 2005; Pan et al., 2004). These striking similarities 
between Drosophila and mammalian FMRP suggest well-conserved function, but 
beg the question of why mammals have an expanded three-member protein 
family. 
 In this study, we investigate the functional conservation of the entire 
Fragile X gene family by expressing each of the three human genes in the 
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Drosophila FXS model with tissue-specific drivers. A wide-ranging series of 
phenotypic tests at the molecular, cellular and ultrastructural levels were selected 
to survey function in nervous system and non-neuronal tissue. A wild-type 
dFMR1 transgene was used as the positive control and each human gene was 
investigated in two independent transgenic lines, all with targeted expression 
driven in either neurons or germ cells within the dfmr1 null mutant background. 
The results show that FMR1 has an evolutionarily conserved function in the 
Drosophila central and peripheral nervous system that is not possessed by either 
FXR1 or FXR2. When all three human genes are targeted to Drosophila neurons, 
only human FMR1 is able to restore brain protein levels in the dfmr1 null mutant, 
and it is just as effective as the native Drosophila FMR1. Similarly, only human 
FMR1 is able to restore normal synaptic architecture in dfmr1 null neurons.  
FXR1 and FXR2 completely lack this ability to compensate.  In contrast, in non-
neuronal tissue all three human genes are equally competent at replacing 
dFMR1 function. When each gene is targeted to the testes, they all fully restore 
male fecundity and rescue testes spermatid axoneme defects. These results 
indicate a unique, evolutionarily conserved role for FMR1 in neuronal 
mechanisms and a broader, shared role for FMR1, FXR1 and FXR2 in non-
neuronal tissue.  
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Results 
Transgenic constructs with targeted pan-neuronal expression 
 Humans have a 3-member gene family composed of the highly similar 
hFMR1, hFXR1 and hFXR2 genes (Zhang et al., 1995). The three gene products 
associate with ribosomes in large complexes thought to cooperatively mediate 
transport of neural mRNAs to specific intracellular locations and inhibit their 
translation until signaled (Ceman et al., 1999; Christie et al., 2009; Dictenberg et 
al., 2008; Khandjian et al., 2004; Siomi et al., 1996; Zhang et al., 1995). In 
Drosophila, the single FMR1 gene (dFMR1) likely represents an ortholog of the 
common ancestor of hFMR1 and its two paralogs. This speculation suggests that 
the functions of the 3-member gene family may subdivide the roles of dFMR1, in 
addition to any newly-evolved functions each gene may serve. The dFMR1 gene 
has a similar sequence homology to all three human genes, so it is not clear 
which, if any, may be the true homolog. To address these questions, we 
engineered transgenic human cDNA constructs for hFMR1, hFXR1 and hFXR2, 
as well as wildtype dFMR1 as a positive control, and expressed each with tissue-
specific drivers in the Drosophila FXS model (dfmr1 null mutant). The generation 
and testing of these transgenic tools is illustrated in Figure 7. 
 cDNA constructs engineered for dFMR1 and each human family gene 
member were sub-cloned downstream of the UAS promoter sequence (5X UAS; 
Fig. 7A). A MYC epitope tag was added at the amino terminus of each transgene 
to track protein expression. The tagged transgenes could then be targeted to 
specific tissues using the pUAST/GAL4 expression system. Each construct was
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Figure 7. Generation of transgenic constructs with targeted neuronal 
expression. (A) The four UAS transgenic constructs generated and tested in this 
study. The positive control is wild-type dFMR1, and the three human genes are 
hFMR1, hFXR1 and hFXR2. All cDNA transgenic constructs are tagged with a 
MYC epitope in the pUAST (5X UAS) expression vector to follow protein 
expression. In all assays, two independent transgenic lines for each human 
transgenic construct were analyzed. (B) The embryonic transformation and 
genetic crossing scheme that was used to introduce each stably integrated UAS 
transgene into the dfmr1 null mutant background and then drive expression with 
the pan-neuronal GAL4 driver elav-GAL4. (C) Western blot analyses of 
transgenic protein expression for the dFMR1 line (control) and two independent 
lines of hFMR1, hFXR1 and hFXR2 (denoted as a/b). Expression from brain 
extracts (1–2-day-old adults) was tested with an anti-MYC antibody against the 
epitope tag common to all four transgenes (see A). Lines were selected for 
comparable transgene expression. The loading control is α-tubulin. (D) Brain 
immunohistochemistry for transgene expression of the dFMR1 line (control) and 
the three human lines (hFMR1, hFXR1 and hFXR2). Drosophila adult brains (1–2 
days old) were probed with anti-MYC to detect the transgene epitope tag. 
Comparable transgene expression occurs in all conditions. Bar, 100 μm. 
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microinjected into genetic background control w1118 embryos (Fig. 7B). Multiple 
stably integrated genomic lines for each transgene were isolated and self-
perpetuating stocks generated. Third chromosome transformants were 
recombined into the dfmr1-null (dfmr150M) background and a stock produced with 
TM6-GFP serving to balance the recombined UAS transgene chromosome (Fig. 
7B). In order to assay rescue of neuronal phenotypes, all transgenic lines were 
crossed with a stock line homozygous for the pan-neuronal driver elav-GAL4 and 
heterozygous for the dfmr150M allele. The resulting experimental stocks were 
homozygous null for dfmr1 with a single copy of the UAS transgene and a single 
copy of the elav-GAL4 driver (Fig. 7B). Two independent transgenic insertion 
lines for each human transgene were used in all experiments, compared to w1118 
with elav-GAL4 driver alone (wild-type control), the dfmr1-null with elav-GAL4 
driver alone (negative control) and UAS-dFMR1 (positive control). Thus, nine 
genetic lines were compared in all subsequent experimental assays. 
 The expression of all transgenes was compared with a combination of 
brain Western blot and immunohistochemistry imaging for the common MYC 
epitope tag in order to select lines with comparable expression (Fig. 7C, D). 
Endogenous dFMRP expression is ubiquitous in neurons and relatively uniform 
between neurons throughout the wild-type Drosophila brain (Fig. 8A). We 
therefore selected elav-GAL4 as the best described pan-neuronal driver 
mimicking this expression (Gatto and Broadie, 2009a). Transgenic lines with high 
and low elav-GAL4 driven expression compared to the UAS-dFMR1 positive 
control were discarded, and two independent insertion lines with comparable 
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expression for each transgene were selected for detailed analyses. Western blot 
analyses of brain protein extracts show comparable MYC epitope tag expression 
levels across all selected transgenic genotypes (Fig. 7C). The protein sizes of 
each transgene are roughly equivalent, albeit with dFMR1 product slightly larger 
and hFMR1 product slightly smaller than the other transgenes. We were careful 
to select lines that did not over-express the transgenes relative to endogenous 
dFMR1 (data not shown). We confirmed that elav-driven transgene expression is 
widespread throughout neurons (Fig. 7D). Anti-MYC labeling of brains from all 
four transgenic lines showed comparable transgene expression levels and 
distribution across genotypes. Importantly, the UAS-dFMR1 positive control was 
indistinguishable from the three human transgenes in brain expression profile 
(Fig. 7D). These lines were therefore selected to systematically test their ability to 
rescue a wide range of dfmr1-null mutant phenotypes. 
 
Only FMR1 restores brain protein levels 
 In both rodents and Drosophila, FMRP/dFMRP acts as a negative 
regulator of protein synthesis in neurons (Lu et al., 2004; Reeve et al., 2005; 
Schutt et al., 2009; Zhang et al., 2001). Loss of this translational regulation is 
believed to be the root cause of all FXS impairments. In the absence of dFMRP, 
total brain protein levels are significantly elevated, particularly during key stages 
of synaptic development and refinement in the late-maturing brain (Tessier and 
Broadie, 2008). We therefore first examined whether this fundamental molecular 
defect was rescued by each of the three human transgenes. Importantly, the 
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dfmr1 null mutant brain is unaltered in size and gross architecture compared to 
wildtype and genetic controls (Fig. 8A). We therefore extracted total protein from 
brains to make a direct comparison of protein levels (Tessier and Broadie, 2008). 
Nine genetic lines were analyzed; the wild-type control, dfmr1 null, UAS-dFMR1 
positive control and two independent lines each for the three human transgenes.  
Null dfmr1 mutants with the elav-GAL4 driver alone (elav/+; dfmr150M/dfmr150M) 
have 22% higher levels of brain protein compared to controls (elav/+; w1118) 
immediately post-eclosion (0-7 hours after eclosion (AE)) (Fig. 8B). Protein levels 
per animal were 16.60.45 g in control compared to 20.20.47 g in the null 
mutant (P<0.01, n=8). The positive transgenic control, elav-GAL4 driven UAS-
dFMR1 in the null mutant background, displayed brain protein levels of 16.40.61 
g, which was 23% lower than the dfmr1 null and showed complete rescue to 
control levels (P<0.01, n=8; Fig. 8B). Two independent transgenic lines of all 
three human genes were assayed for brain protein levels. Both UAS-hFMR1 
lines (light and dark bars in Fig. 8B) showed exactly the same effect of lowering 
brain protein levels by 28% compared to the dfmr1 null, restoring levels 
indistinguishable from wild-type control (15.830.56 g, 15.80.4 g; n=8, 
P<0.001). In contrast, elav-GAL4 driven neuronal expression of the two human 
paralogs, UAS-hFXR1 and UAS-hFXR2, maintained brain protein levels 
comparable to dfmr1 nulls, with no indication of rescue. For UAS-hFXR1, the two 
independent lines showed levels of 21.20.43 g and 21.10.63 g (Fig. 8B). For 
UAS-hFXR2, the protein levels were 19.340.61 g and 20.10.66 g. There
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Figure 8. Only hFMR1 rescues elevated protein levels in the dfmr1 null 
brain. (A) Comparison of dFMRP expression in the wild-type control (w1118) and 
the dfmr1 null (dfmr150M) adult Drosophila brain, which were used as positive and 
negative controls in all assays. Acutely dissected brains (2 days old) were 
immunolabeled with anti-dFMRP (green) and anti-GFP (red) to reveal a 
transgene marker in the mushroom body learning/memory center. Note that the 
null mutant brain is of normal size with normal gross architecture. Bar, 100 μm. 
(B) Total brain protein was extracted from young adult (0–7 hours old) animals 
and quantified with a MicroBCA assay. The six genotypes that were compared 
are: w1118 control, dfmr1 null (dfmr150M), elav-GAL4 driving UAS-dFMR1 (positive 
control), and two independent lines each (light and dark gray bars) of UAS-
hFMR1, UAS-hFXR1 and UAS-hFXR2 expression in the dfmr1 null background. 
Each bar shows the average protein levels in μg per head. Sample size: 10–20 
pooled heads per sample, n=8. Significance: **P<0.01; ***P<0.001. 
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was no significant difference between any of these four lines relative to each 
other or compared to the dfmr1 null condition. All four hFXR1 and hFXR2 
transgenic lines maintained highly significantly (P<0.001) elevated brain protein 
levels compared to wildtype. 
 These results demonstrate that only human FMR1 and not its paralogs, 
hFXR1 and hFXR2, can rescue the hallmark elevation of brain protein levels in 
the dfmr1 null back to the control state. Human FMR1 was just as effective as 
Drosophila FMR1 in restoring normal brain protein levels, indicating completely 
conserved function in this fundamental role. The fact that hFXR1 and hFXR2 lack 
this function may be predicted by the fact that these proteins have not been 
shown to act as negative translational regulators (Laggerbauer et al., 2001). 
 
Only FMR1 restores brain circuit synaptic architecture  
 At a cellular level, the hallmark defect in FXS patients and disease models 
is inappropriate synaptic connectivity (Braun and Segal, 2000; Bureau et al., 
2008; Comery et al., 1997; Gatto and Broadie, 2008; Hanson and Madison, 
2007; Tessier and Broadie, 2008). In both mouse and Drosophila models, 
synapse architecture also appears immature or developmentally arrested. We 
first examined synapse connectivity in the central brain, based on well-
established dfmr1 phenotypes. Null dfmr1 mutants exhibit strikingly abnormal 
circadian rhythm patterns, with a complete loss of rhythmicity in the absence of 
environmental entrainment (Bushey et al., 2009; Dockendorff et al., 2002; Inoue 
et al., 2002; Sofola et al., 2008). Although mouse FMR1 knockouts show only 
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mild impairments, the FMR1/FXR2 double knockout is likewise entirely 
arrhythmic (Zhang et al., 2008). In Drosophila, circadian activity is controlled by 
well-defined clock circuitry, in which the small ventrolateral (sLNv) neurons are 
sufficient for pacemaker activity (Grima et al., 2004; Renn et al., 1999; Stoleru et 
al., 2004). These neurons express the neuropeptide Pigment Dispersing Factor 
(PDF) and exhibit a characteristic branching pattern with axonal processes 
projecting dorsally to a defasiculation point in the protocerebrum and then 
synaptic processes extending medially (Gatto and Broadie, 2009a; Helfrich-
Forster, 1995; Helfrich-Forster, 2005).  In dfmr1-null mutants, sLNv processes are 
over-elaborated and extend beyond their normal termination points (Dockendorff 
et al., 2002; Gatto and Broadie, 2009a; Morales et al., 2002).  Given the 
synergistic effect FMR1 and FXR2 on rhythmicity in mice (Zhang et al., 2008), it 
might be predicted that the proteins possess redundant or overlapping functions 
in the clock circuit. To test this hypothesis, we assayed the ability of each human 
transgene to rescue the dfmr1 defects in the central clock circuit (Fig. 9). 
 Brains labeled with anti-PDF clearly display the dorsal sLNv projections 
into the protocerebrum (Fig. 9A).  At the point of axonal defasiculation, the 
processes split into a localized array of small synaptic projection at the dorsal 
horn and into the protocerebrum. These projections are bilaterally symmetrical on 
the two sides of the brain (Fig. 9A; middle and right). Null dfmr1 animals exhibit a 
highly significant (n10; P<0.001) increase in the number of PDF boutons 
compared to controls (Fig. 9B). Wild-type terminals contain a mean of 45.11.3 
boutons compared to 67.62.0 in the dfmr1 null. Thus, the mutant condition
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Figure 9. Only hFMR1 rescues clock neuron synapse arbors in dfmr1 null 
mutants. (A) Representative images of small ventrolateral (sLNv) clock neurons 
in the adult brain labeled with anti-PDF. The low-magnification image on the left 
shows the bilaterally symmetrical sLNv projections, terminating in synaptic arbor 
projections (arrow) in the dorsal protocerebrum. Note the PDF-positive punctae 
marking the synaptic boutons. Bars, 20 μm (A, left panel); 10 μm (A, middle and 
right panels). (B) Representative images of the sLNv synaptic arbors from the six 
genotypes assayed: w1118 (control), dfmr150M null (dfmr1), and the null 
background with elav-GAL4-driven UAS-dFMR1, UAS-hFMR1, UAS-hFXR1 and 
UAS-hFXR2. Bar, 10 μm. (C) Quantification of the number of PDF-positive 
punctae per synaptic arbor in the six genotypes shown. Sample size: n≥10 
animals for each genotype. Significance: ***P<0.001 for all comparisons. 
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shows a ~50% increase in PDF-positive synaptic boutons (Fig. 9C). Neuronal 
expression of wild-type dFMR1 completely rescues the synaptic overgrowth 
characterizing the null mutant, and the terminals become clearly more restricted 
in extent and refined in number of synaptic boutons (Fig. 9B).  The expression of 
wild-type dFMR1 results in the differentiation of 45.01.2 boutons, a number 
indistinguishable from control and significantly (n10; P<0.001) rescued 
compared to the dfmr1-null condition (Fig. 9C). 
 Each human transgene was next expressed in turn to evaluate rescue of 
the sLNv synaptic arbor defect in dfmr1 nulls. First, hFMR1 expression in neurons 
was assayed, and showed complete rescue of the overgrowth defect (Fig. 9B). 
Targeted hFMR1 resulted in 42.61.2 PDF-positive boutons in the sLNv arbor, a 
rescue as complete as the native Drosophila gene (Fig. 9C). Next, the two 
paralogs were assayed in turn. At a qualitative level, sLNv synaptic terminals 
appear as overgrown with hFXR1 or hFXR2 expression as in the purely null 
mutant state (Fig. 9B). Indeed, quantification of PDF bouton number fails to show 
any significant rescue by either of these transgenes. hFXR1 expression resulted 
in 67.02.6 boutons, and hFXR2 expression similarly resulted in 68.51.2 
boutons (Fig. 9C). Neither value is significantly different from the dfmr1 null 
(67.62.0), and both are very significantly elevated compared to the control 
(45.11.3; n10; P<0.001). Thus, both Drosophila and human FMR1 similarly 
and completely rescue the synaptic defect in the clock neurons, whereas neither 
human paralog exerts any detectable compensatory function.   
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Only FMR1 restores neuromuscular junction synaptic architecture 
 In the Drosophila FXS model, the glutamatergic neuromuscular junction 
(NMJ) synapse is extremely well characterized (Gatto and Broadie, 2008; Pan et 
al., 2008; Zhang et al., 2001). The size and accessibility of this synaptic arbor, 
combined with the wealth of synaptic markers and structural information, make 
this terminal particularly suited to a systematic investigation. Null dfmr1 mutants 
display defects on many levels of NMJ synaptic architecture, including grossly 
elevated synaptic area, increased synaptic branching and the formation of 
supernumerary synaptic boutons (Gatto and Broadie, 2008; Pan et al., 2008; 
Zhang et al., 2001). Most strikingly, developmentally arrested mini (or satellite) 
boutons accumulate in the absence of dFMRP function (Gatto and Broadie, 
2008), which likely represent an early stage of normal bouton maturation 
(Beumer et al., 1999; Gorczyca et al., 2007; Ruiz-Canada et al., 2004). To 
compare synaptic development, we co-labeled junctions with presynaptic (HRP 
membrane marker) and postsynaptic (DLG scaffold marker) antibody probes to 
quantify all of these features in dfmr1 null, wild-type control, elav-GAL4 
(presynaptic) driven UAS-dFMR1 positive control, and all three UAS human 
transgenes in the dfmr1-null mutant background. 
 Labeling for HRP delineates the innervating presynaptic neuron (red), and 
anti-DLG reveals the postsynaptic domain (green) of the target muscle (Fig. 
10A). The positive transgenic control of elav-GAL4 driven UAS-dFMR1 fully 
rescued both the enlarged junctional area and increased synaptic branching that 
characterizes the dfmr1-null condition (Fig. 10B, C). To quantify synaptic area,
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Figure 10. Only hFMR1 rescues synapse architecture in dfmr1 null mutants. 
The wandering third instar NMJ synapse was co-labeled with presynaptic and 
postsynaptic markers and compared between the six genotypes: wild-type 
control, dfmr1 null mutants, and elav-GAL4-driven expression in the dfmr1 null 
background of UAS-dFMR1 (positive control) and two independent lines each of 
UAS-hFMR1, UAS-hFXR1 and UAS-hFXR2. (A) Representative images of the 
muscle 4 NMJ labeled for presynaptic HRP (red) and postsynaptic DLG (green). 
Three example synaptic arbors are shown for each of the six genotypes. Bar, 10 
μm. Quantification of junction area measured based on DLG domain expression 
(B) and the number of synaptic branches measured based on HRP labeling (C). 
Sample size: n≥10 animals for each genotype. Significance: ***P<0.001. 
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the junction delimited by DLG expression was measured (control, 26413 m2; 
dfmr1 null, 35911 m2; n>10, P<0.001; Fig. 10B). Presynaptic dFMR1 
expression completely restored junctional area to control levels (2676 m2; 
n>10, P<0.001). To quantify branching, HRP-labeled synaptic projections with 
more than two boutons were counted (control, 2.20.14; dfmr1 null 3.20.1; 
n>10, P<0.001; Fig. 10C). Presynaptic dFMR1 expression completely restored 
synaptic branching from the elevated mutant levels (2.20.14 branches; n>10, 
P<0.001). Strikingly, human FMR1 was equally able to completely restore 
synaptic junctional area and arbor branching to wild-type levels (2626 m2 area, 
2.180.16 branches; n>10, P<0.001; Fig. 10B,C). In sharp contrast, the two 
paralogs, hFXR1 and hFXR2, were totally unable to restore synaptic area in the 
null mutant (hFXR1, 3525.5 m2; hFXR2, 3534.1 m2, n>10; Fig. 10B). 
Similarly, both hFXR1 and hFXR2 failed to restore normal synaptic branch 
number in the mutant (3.30.17 branches and 3.40.28 branches, respectively; 
n>10; Fig. 10C). Thus, only human FMR1 has a conserved function in 
maintaining gross synaptic architecture, and hFXR1 and hFXR2 completely lack 
this ability. 
 dFMRP plays a key role in limiting synaptic bouton number and regulating 
the normal rate of bouton differentiation. To quantify mature type Ib bouton 
number, HRP/DLG co-labeled varicosities >2 m in minimum diameter were 
counted within individual synaptic arbors (Fig. 11A). Null dfmr1 mutants exhibit a 
very significantly increased number of synaptic boutons compared to controls 
(dfmr1, 29.10.7; control, 19.70.5; n>10, P<0.001; Fig. 11B). Presynaptic elav-
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Figure 11. Only hFMR1 rescues synapse bouton differentiation in dfmr1 
null mutants. (A) Representative high magnification images of synaptic boutons. 
Mature type 1b boutons were defined as boutons >2 μm in minimal diameter. 
Satellite mini-boutons, representing an early stage in bouton differentiation, are 
<2 μm in diameter and are directly attached to a mature type 1b bouton (arrows). 
Developmentally arrested mini-boutons accumulate in the dfmr1 null mutant. Bar, 
2 μm. Quantification of the number of mature boutons (B) and mini-boutons (C) 
per synaptic arbor in the six genotypes. The two independent lines for each 
human transgene were not significantly different, and were therefore pooled for 
these comparisons. Sample size: n≥10 animals for each genotype. Significance: 
***P<0.001 for all comparisons. 
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GAL4 driven expression of the UAS-dFMR1 positive control completely rescued 
bouton number back to control levels (19.80.6; n>10, P<0.001; Fig. 11B). 
Strikingly, human FMR1 was equally able to completely rescue synaptic bouton 
number to the wild-type array (200.5 boutons; n>10, P<0.001; Fig. 11B). 
Conversely, the two paralogs, hFXR1 and hFXR2, were totally incapable of 
restoring the elevated bouton number in the dfmr1 null (271.0 and 281.2 
boutons, respectively; n10, Fig. 11B). A particularly key feature of the null 
mutant phenotype is the accumulation of small, immature mini-boutons (Fig. 11A; 
arrows). These boutons were elevated 10-fold in the dfmr1 null compared to 
genetic controls (dfmr1, 4.90.4; control, 0.460.14; n>10, P<0.001; Fig. 11C). 
The positive control dFMR1 was able to strongly rescue mini-bouton number 
back to wild-type levels (0.780.1; n>10, P<0.001; Fig. 11C). With the same 
efficiency, human FMR1 also restored mini-bouton numbers to control levels 
(0.940.17; n>10, P<0.001; Fig. 11C). However, the two paralogs, hFXR1 and 
hFXR2, were totally incapable of restoring the elevated mini-bouton number, 
which remain just as elevated as in the dfmr1-null mutant condition (4.50.36 
mini-boutons and 4.40.4 mini-boutons, respectively; no significant difference 
from dfmr1; n10; Fig. 11C). These findings further delineate a specific role for 
FMR1 in the control of synaptic architecture and bouton maturation that cannot 
be in the least compensated by its FXR paralogs. 
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Human FMR1, FXR1 and FXR2 all restore male fecundity and spermatogenesis 
 FXS patients display a range of non-neuronal symptoms, the most 
prominent of which is impaired testicular development in male patients 
(Lachiewicz and Dawson, 1994; Nistal et al., 1992; Turner et al., 1980). Both 
mouse and Drosophila disease models are similarly characterized by enlarged 
testes and reduced testicular function (Slegtenhorst-Eegdeman et al., 1998; 
Zhang et al., 2004). Null dfmr1 males exhibit severely reduced fertility due to 
immotile sperm (Zhang et al., 2004). We utilized these defects as a sensitive 
assay for the non-neuronal roles of the three human genes. Each transgene was 
driven in the male germline with a nanos GAL4 driver line (nos-GAL4; Fig. 12A). 
Males of each genotype were mated to virgin wild-type females and the number 
of resulting progeny assessed. Nine male genotypes were tested: wild-type 
control, dfmr1 null, and the UAS-dFMR1 positive control and two independent 
lines each for the three human transgenes in the dfmr1 null mutant background. 
 We first confirmed that nanos-GAL4 drives expression in the testes as 
previously described (Fig. 12C) (Schulz et al., 2004).  Using the common MYC 
epitope tag on all 4 transgenes, similar transgene expression was present in all 
cases, with the highest expression in germline stem cells and lower expression 
throughout the spermatagonia, as expected (Fig. 12C). We then carried out male 
brooding tests with wildtype, dfmr1 null and all 4 transgenic lines. All male 
genotypes where paired with three w1118 virgin females, allowed to mate for 9 
days and progeny counted for a further 9 days. Wild-type control males produced 
an average of 138.51.3 progeny under these conditions (n=8 trials; Fig. 12B). In
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Figure 12. All three human genes rescue dfmr1 mutant male fecundity. (A) 
The crossing scheme used to assay transgene function in the testes. The 
germline nos-GAL4 line was used to drive UAS-dFMR1 (control) and the three 
human transgenes (UAS-hFMR1, UAS-hFXR1 and UAS-hFXR2) in the dfmr1 
null mutant background. (B) Quantification of the number of progeny per male for 
all six genotypes. The dfmr1 null mutant is effectively sterile owing to non-motile 
sperm. The two independent lines for each human transgene were not 
significantly different in any case, and were therefore pooled for these 
comparisons. (C) Representative images of adult male testes (<24 hours) with 
the nos-GAL4 line driving expression of the four MYC-tagged transgenes. Anti-
MYC labeling was used to detect UAS-dFMR1, -hFMR1, -hFXR1 and -hFXR2. 
Expression was highest in the germline stem cells (arrow) and early spermatid 
progeny, as expected for the nos-GAL4 driver. Bar, 25 μm. 
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sharp contrast, the dfmr1 null was completely sterile in these trials, producing no 
viable progeny. The positive transgenic control of UAS-dFMR1 driven by nos-
GAL4 in the null background completely rescued the male fecundity defect 
(135.31.5 progeny, n=8 trials; Fig. 12B). To our surprise, all three human genes 
were similarly capable of completely rescuing mutant male performance to 
control levels. The human FMR1 gene restored the number of progeny to 
136.52.0 per male. The two paralogs, hFXR1 and hFXR2, similarly restored the 
mutant male output to 135.11.0 and 139.31.1 progeny, respectively (Fig. 12B). 
Thus, all three human genes fully and equally compensate for the loss of dFMRP 
in the testes, indicating that they share the conserved function required for male 
fecundity. 
 Loss of male fecundity in the Drosophila FXS model is caused by defects 
in sperm tail microtubule organization, which renders the dfmr1-null sperm 
immotile (Zhang et al., 2004). In wild-type testes, the spermatid axoneme 
contains a 9+2 microtubule configuration of nine outer doublets and a single 
central pair (Fig. 13A). As the axoneme develops, accessory proteins are added 
to this core microtubule structure, giving the axoneme its characteristic pinwheel 
cross-section (see control inset). In dfmr1 null spermatids, the central pair 
microtubules are routinely lost (Fig. 13A), while the outer ring microtubule 
doublets are often deranged (Fig. 13B). The central pair is required for the 
motility of the sperm tail. This microtubule defect is not caused by misregulation 
of the MAP1B homolog futsch, a key cause of microtubule defects in neurons 
(Hummel et al., 2000; Zhang et al., 2001), as futsch is not detectably expressed
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Figure 13. All three human genes rescue dfmr1 mutant spermatogenesis 
defects. (A) Representative images of the testes spermatid ultrastructure for all 
six genotypes. Insets show high-magnification views of a single axoneme. Wild-
type sperm tails display the characteristic 9+2 microtubule arrangement of nine 
outer doublets and the central pair (inset). The dfmr1 null mutants exhibit 
disordered microtubules with the central pair missing (inset). Bar, 250 nm. (B) 
Higher magnification views of the sperm tail axoneme. Control axonemes show a 
perfectly arranged 9+2 microtubule organization. For dfmr1 mutants, several 
examples are shown displaying the range of microtubule disruption phenotypes, 
including the missing central pair, malformed outer ring. Bar, 50 nm. (C) 
Quantification of the percentage of spermatids displaying a missing central pair 
of microtubules from the axoneme for all six genotypes. Significance: ***P<0.001. 
 64 
outside of the nervous system. Therefore, this function represents a clearly non-
neuronal role for dFMR1 utilizing an independent molecular mechanism. 
 To assess the human gene family function, we compared spermatid 
ultrastructural differentiation in all three UAS human transgenes in the dfmr1-null 
mutant background. Wild-type controls exhibited a consistent 9+2 microtubule 
array in cross-section of the mature bundled spermatid tails in the testes (Fig. 
13B). In contrast, dfmr1 axoneme abnormalities included variably skewed and 
malformed outer doublets and the central pair microtubules often completely 
missing, or occasionally only one microtubule in the central pair was present (Fig. 
13B). In wild-type controls, only 7.11.2% (n=751) of spermatid axonemes lacked 
a detectable microtubule central pair, whereas dfmr1 null mutants displayed a 7-
fold increase to 49.32.5% missing the central pair (n=1152, P<0.001; Fig. 13C). 
Expression of the dFMR1 positive transgenic control was able to strongly restore 
this axoneme defect (18.44.5%) in the null mutant (n=588, P<0.001; Fig. 13C). 
To our surprise, all three genes in the human gene family (hFMR1, hFXR1 and 
hFXR2) were also able to fully restore axoneme microtubule architecture to 
levels comparable with wild-type controls (Fig. 13A). Human FMR1 expression 
produced sperm axonemes indistinguishable from wildtype, with only 7.11.9% 
missing the central microtubule pair (n=641, P<0.001; Fig. 13C). The two 
paralogs were also fully proficient in this setting, with hFXR1 rescuing to 
2.10.7% missing the central pair (n=1043, P<0.001) and hFXR2 rescuing to 
4.51.2% missing the central pair (n=1382, P<0.001; Fig. 13C). In this non-
neuronal assay of function, these results clearly demonstrate complete 
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redundancy in the function of all three human genes in successfully restoring 
both male fecundity and the underlying spermatid differentiation defects of dfmr1-
null mutant animals. 
Discussion 
 Fragile X syndrome (FXS) is caused solely by loss of the FMR1 gene 
product.  However, humans also have two highly similar gene family paralogs, 
FXR1 and FXR2, whose function remains comparatively unexplored. The three 
gene products have been identified as part of the same molecular complex in 
neurons and other cells, but are clearly not functionally redundant in the FXS 
disease condition (Bakker et al., 2000; Ceman et al., 1999; Schenck et al., 2001; 
Zhang et al., 1995). Both homo- and heterodimerization within the gene family 
may occur, although homodimerization may be more common in vivo (Tamanini 
et al., 1999b). FMRP and FXR2P can be found in complexes lacking FXR1P, 
indicating possible unique interactive or redundant functional overlap of at least 
these two proteins (Christie et al., 2009; Tamanini et al., 1999b). The expression 
of FXR1 and FXR2 appear to remain unchanged in FXS patients (Agulhon et al., 
1999) and the mouse FXS model, (Bakker et al., 2000) and mutations in FXR1 or 
FXR2 are not associated with FXS or any other disease condition. Nevertheless, 
FXR1 is clearly essential, as mouse and zebrafish FXR1 knockouts are lethal 
shortly after birth due to cardiac and muscle defects (Mientjes et al., 2004; Van't 
Padje et al., 2009), showing that FXR1 has taken on a unique vertebrate muscle 
function. This is consistent with elevated expression of FXR1 in muscles 
(Mientjes et al., 2004). It is not clear what role FXR1 may play in neurons, where 
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the protein is present at a lower level. In contrast, mouse FMR1 and FXR2 single 
knockouts display clear neuronal phenotypes (Bontekoe et al., 2002; Comery et 
al., 1997; Hoogeveen et al., 2002), and the FMR1/FXR2 double knockout 
exhibits exaggerated behavioral and neural circuit defects (Spencer et al., 2006; 
Zhang et al., 2008; Zhang et al., 2009). These findings show that FXR2, at least, 
plays a role in neurons with functional consequences overlapping FMR1 
requirements.  However, it is not at all clear whether this link reveals an 
interaction between FMR1 and FXR2 in the same mechanism, or partial 
compensation permitted because of functional overlap between these two 
proteins. 
 Drosophila FMR1 may resemble the common ancestral gene of the 
vertebrate gene family. dFMR1 shows high sequence homology, domain 
conservation and functional properties to hFMR1 (Zhang et al., 2001; Zhang et 
al., 2004), but is just as similar to hFXR1 and hFXR2. To validate and further 
develop the Drosophila FXS model, it was critical to determine the evolutionary 
conservation of dFMR1 relative to the three human genes. For the last decade, 
the repeatedly posed question has been whether the Drosophila model studies 
the role of FMR1, FXR1 or FXR2, or some combination of all three. Given that 
FXS is caused solely by loss of FMR1, does it play a unique function in the 
nervous system? If so, is the study of dFMR1 a good model for this disease-
dependent hFMR1 requirement? To answer these questions, we expressed each 
of the three human genes independently in the Drosophila FXS model and tested 
for their functional rescue of a carefully selected, diverse range of null mutant 
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phenotypes. Specifically, we selected the core molecular and cellular phenotypes 
distributed over the widest range of tissues: the brain, neuromusculature, and 
testes. Our findings reveal three important conclusions: i) human FMR1 replaces 
all Drosophila FMR1 functions indicating complete functional conservation, ii) 
FMR1 has a unique function in Drosophila peripheral and central neurons as a 
translational regulator sculpting synaptic connections, which cannot be 
compensated for by either FXR1 or FXR2, and iii) the entire human gene family 
can fully replace the dFMR1 requirement in the testes, demonstrating a 
fundamentally different mechanistic requirement in non-neuronal cells. 
 The hallmark molecular requirement for FMRP is as a negative regulator 
of translation (Laggerbauer et al., 2001; Schutt et al., 2009; Zalfa et al., 2003; 
Zhang et al., 2001). FMRP is present in actively translating polyribosomes and 
inhibits the translation of mRNA targets (Khandjian et al., 2004; Napoli et al., 
2008; Reeve et al., 2005; Schutt et al., 2009; Stefani et al., 2004; Yang et al., 
2009). In the absence of dFMRP, total protein levels are elevated in the 
Drosophila brain, particularly during the late developmental stages of 
synaptogenesis and early-use synaptic refinement in newly-eclosed animals 
(Tessier and Broadie, 2008).  This is consistent with the mouse FMR1 knockout, 
which also exhibits increased protein synthesis in the brain (Qin et al., 2005). 
This increase in protein levels is predicted as dFMRP, like mouse FMRP, has 
been established as a negative regulator of protein translation (Costa et al., 
2005; Reeve et al., 2005; Zhang et al., 2001). Using targeted neuronal 
expression, only dFMR1 and hFMR1 can restore elevated brain protein levels 
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back to the wild-type condition in the Drosophila FXS brain. Human FMRP is just 
as effective as the native fly protein in limiting brain protein expression. Whereas 
FMR1 is both necessary and sufficient for this mechanism in neurons, human 
FXR1 and FXR2 are completely unable to rescue this phenotype. Therefore, 
despite high functional domain conservation, the FXR paralogs are unable to 
compensate for FMR1 in the mechanism of protein regulation in neurons. 
 In mammals, FMR1 and FXR2 work synergistically (or redundantly) to 
regulate circadian rhythmicity, with a dramatic impairment only in the double 
knockout condition (Zhang et al., 2008). While each single mutant animal shows 
a significant shift of circadian periodicity, the double knockouts are completely 
arrhythmic and fail to entrain to light. This phenotype is nearly identical to the 
dfmr1-null defect in circadian activity, which has been known for many years 
(Dockendorff et al., 2002; Inoue et al., 2002). These results suggest that FMR1 
and FXR2 may cooperate, or be functionally redundant, within the circadian clock 
neural circuit in a mechanism shared between mammals and flies. In Drosophila, 
the central brain clock circuit is particularly well characterized (Chang, 2006; 
Helfrich-Forster, 2005; Nitabach and Taghert, 2008).  Much attention has 
focused on the small ventrolateral clock neurons, which secrete the neuropeptide 
PDF and are sufficient for maintaining circadian rhythms (Grima et al., 2004; 
Renn et al., 1999; Stoleru et al., 2004). In dfmr1-null animals, it has long been 
known that these neurons produce over-elaborated and over-extended synaptic 
arbors in the protocerebrum (Gatto and Broadie, 2009a; Morales et al., 2002; 
Reeve et al., 2005; Sekine et al., 2008). Among the human gene family, only 
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hFMR1 was able to rescue the synaptic defect in this central circuit. Indeed, 
hFMR1 was just as proficient as the native dFMR1, indicating full functional 
conservation of FMR1 function between flies and humans. In contrast, hFXR1 
and hFXR2 expression in the clock circuit had absolutely no effect on the null 
mutant phenotype.  Therefore, it is likely that the behavioral augmentation seen 
in mammals between FMR1 and FXR2 is a consequence of effects on 
complementary pathways that function in the same readout.  In any case, it is 
clear the evolutionarily conserved role in the refinement of central synaptic 
connections is possessed only by FMR1 and not its two paralogs, at least in this 
circuit. 
 The hallmark cellular defect in FXS patients and genetic disease models is 
the over-proliferation of synaptic connections, many of which appear to be 
immature (Grossman et al., 2006; Irwin et al., 2001). Although most research has 
focused on postsynaptic dendritic spines, apposing presynaptic bouton 
specializations obviously accumulate in parallel. In the Drosophila FXS model, 
both presynaptic boutons and postsynaptic dendrites are over-grown and over-
elaborated in the absence of dFMR1, and we have demonstrated that this is a 
cell-autonomous requirement with neurons (Gatto and Broadie, 2008; Pan et al., 
2004). Our previous studies of the well-characterized NMJ synaptic arbor have 
established a solely presynaptic requirement for dFMR1 in governing terminal 
area, synaptic branching and the formation of synaptic boutons (Gatto and 
Broadie, 2008).  Null dfmr1 synapses display increased terminal area, synaptic 
branching and supernumerary synaptic boutons. As in the central brain, our work 
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here demonstrates that only dFMR1 and hFMR1 are able to curb growth and 
restore normal synaptic architecture in the null mutant.  In sharp contrast, the 
FXR paralogs do not possess this ability to any detectable degree.  Thus, FMR1 
has the unique ability to sculpt synaptic connections also in the context of the 
Drosophila peripheral nervous system. 
 A defining feature of the overgrown synaptic connections arising in the 
absence of dFMR1 is that they appear structurally immature. The NMJ is 
characterized by the accumulation of so-called “mini” or “satellite” boutons in 
dfmr1-null mutants (Gatto and Broadie, 2008). These immature boutons 
represent a developmentally arrested state of an otherwise normal stage of 
bouton maturation (Ashley et al., 2005; Beumer et al., 1999; Dickman et al., 
2006; Torroja et al., 1999). In the absence of dFMR1, there is a 50% increase in 
the number of structurally mature boutons, but a striking 10-fold elevation in the 
abundance of these immature mini-boutons. Only the transgenic introduction of 
dFMR1 and hFMR1 can overcome this developmental arrest, restoring the 
normal number of mature synaptic boutons and eliminating the accumulation of 
mini-boutons. FXR1/2 in contrast, exhibit no restorative activity in synaptic 
bouton differentiation. Although functional domains appear similar between all 
members of the human gene family, as well as dFMR1, it is not established that 
FXR1P and FXR2P bind the same target mRNAs as FMRP or, if so, regulate 
them in the same fashion. Indeed, differential binding and regulative activities 
have been proposed (Cavallaro et al., 2008; Tamanini et al., 1999a). In the 
Drosophila context, we have shown here that only FMR1 has any detectable role 
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in regulating neuronal protein expression. Clearly neuronal expression of either 
FXR1 or FXR2 is not sufficient to remodel synaptic structure, at two very different 
classes of synapse, or to maintain the normal program of synaptic differentiation. 
We therefore conclude that FMR1 has a unique function in mRNA regulation 
required for the proper development and differentiation of synaptic connections. 
 The critical breadth of this study came from investigating a key non-
neuronal FXS phenotype: the role of FMR1 in testes development and the 
maintenance of male fecundity.  Male FXS patients have enlarged testes and 
reduced fecundity accompanied by spermatogenesis defects (Lachiewicz and 
Dawson, 1994; Nistal et al., 1992; Turner et al., 1980). The Drosophila FXS 
model similarly exhibits enlarged testes and decreased fecundity caused by 
defects in spermatid maturation resulting in immotile sperm (Zhang et al., 2004). 
Normal mature sperm tails present the “9+2” microtubule configuration of nine 
outer doublets and a single, specialized central pair. In dfmr1-mutant spermatids, 
the central pair microtubules are often completely lost, while the outer ring 
microtubule doublets are more occasionally disordered. To our initial 
amazement, all three human family genes (FMR1, FXR1 and FXR2) are equally 
capable of fully providing this requirement.  Each gene driven by a germline 
promoter completely restores the null male mutant fecundity and rescues all 
aspects of the testes development defects. Ultrastructural analyses show normal 
“9+2” microtubule architecture in all cases. Thus, in contrast to the FMR1-specific 
role in neurons, FMR1 and its two FXR paralogs show complete functional 
overlap and competency in this non-neuronal context. These results suggest the 
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startling conclusion that FMR1 functions in a fundamentally different way in the 
nervous system compared to the testes. 
 It is important to note that these experiments were performed using the 
longest cDNA constructs of each gene, and thus may not take into account the 
function of unique splice isoforms. At least FMR1 and FXR1 are expressed as 
differential isoforms, with some transcripts expressed more strongly in some 
tissues than others (Davidovic et al., 2008; Denman and Sung, 2002; Huang et 
al., 1996; Khandjian et al., 1998; Kirkpatrick et al., 1999; Sittler et al., 1996). The 
fact that the full-length FMR1 construct rescues all phenotypes indicates that the 
FMR1 transcript heterogeneity is dispensable, at least at the level of phenotypes 
assayed here.  However, the same may not be true for FXR1. Note that we have 
not expressed transgenes postsynaptically in muscle, and therefore cannot rule 
out some trans-synaptic mechanism by which muscle FXR1 could potentially 
alter dfmr1 NMJ phenotypes.  This seems unlikely, however, given that all NMJ 
structural phenotypes are fully rescued with presynaptic dFMR1 (Gatto and 
Broadie, 2008). In regards to FXR2, our findings are surprising because previous 
studies suggest that FXR2 may have some redundancy with FMR1 within 
neurons. Nevertheless, in our dispersed array of neural assays, there was no 
FXR2 function detected, suggesting that neuronal roles for FXR2 appear 
mammal specific. The primary conclusion is that the much greater complexity of 
the mammalian nervous system appears to require unique functions mediated at 
least by FXR2. These mechanisms are sufficiently similar that they can somehow 
impinge on FMR1 function. 
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Methods 
Drosophila stocks and genetics 
 All Drosophila stocks were maintained at 25C on standard cornmeal 
agar. The control genotype was w1118 with a single copy of one of two GAL4 
driver lines: w1118; elav-GAL4/+ (neuronal assays) and w1118; nos-GAL4/+ 
(germline assays).  The null mutant genotype was homozygous dfmr150M (Zhang 
et al., 2001) with a single copy of the two GAL4 driver lines: dfmr150M; elav-
GAL4/+ and dfmr150M; nos-GAL4/+. For brain staining, the genotypes UAS-
GFP/+; OK107/+ and UAS-GFP/+; dfmr150M; OK107/+ were used to identify the 
mushroom body with GFP antibodies (Fig. 8).  As described below, the four 
transgenic UAS constructs were UAS-MYC-HA-dFMR1 (positive control) and the 
three human transgenes UAS-MYC-hFMR1, UAS-MYC-hFXR1 and UAS-MYC-
hFXR2. Third chromosome transformants were recombined with the dfmr150M 
allele by conventional genetic techniques. The GAL4 driver lines elav-GAL4 
(P[GawB]elavC155); (P{w[+mC]=GAL4-elav.L}2/CyO) and nos-GAL4 
(P{w[+mC]=GAL4-nos.NGT40}); (P{w[+mC]=GAL4::VP16-nos.UTR}MVD2) were 
obtained from the Bloomington Drosophila Stock Center (Bloomington, IN).   
 
Molecular techniques 
Generation of UAS-dFMR1 control line 
 The control UAS construct of the wild-type Drosophila FMR1 transgene 
was generated through three cloning reactions. First, the dfmr1 coding sequence 
was amplified from w1118 total cDNA by PCR using the Expand Long Template 
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PCR System (Roche, Indianapolis, IN) according to manufacturer protocol with 
primers 5-GCTCGACGAA TGGAAGATCTCCTCGTGGAAGTTCGGCTC-3 and 
5-GTCTAGATATGTGGCGG CTACATTCAAGGACATC-3. This sequence 
spans from the first base of the dfmr1 start codon through 155 bases into the 
3UTR. Next, the product was double digested with XhoI and XbaI and ligated 
into a similarly digested pUAS-T vector to create pUAS-dfmr1. A MYC-HA tag 
was created using oligo 5-GGAATTCATGGAACAAAAA 
CTTATTAGCGAAGAAGATCTTGCATATCCGTATGATGTTCCGGATTATGCAG
CGGCCGCAA-3 and the reverse complement. The product was double digested 
with EcoRI and NotI and ligated into similarly digested pUAS-dfmr1. Last, the 
dfmr1 DNA from 155bp from the start of the 3UTR to 76bp after the end of the 
3UTR was amplified from genomic DNA by PCR using primers 5-
GTCTAGACACAACAACCAACAACAACCACAC-3 and 5-GTCTA 
GACCCGCACTAATTCATGAAGAAATTAACAAC-3. The product was digested 
with XbaI and ligated into the similarly digested pUAS-dfmr1 containing the MYC-
HA insert. The final plasmid pUAS-MYC-HA-dFMR1 was purified and confirmed 
by sequencing. The plasmid was microinjected into w1118 embryos by Genetic 
Services, Inc. (Cambridge, MA). Transformants with stably integrated genomic 
inserts were identified and mapped to chromosome locations using standard 
genetic techniques. 
Generation of UAS-hFMR1/hFXR1/hFXR2 lines 
All three human gene family cDNAs in the pTL1 vector were kindly provided by 
Edouard W. Khandjian, URGHM, Centre de Recherche Hôpital St-François 
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d'Assise, Québec, Canada. The hFMR1 cDNA was double digested from the 
pTL1 vector with EcoRI and PstI and subcloned into pBluescript II to provide the 
necessary BglII site. The hFXR1 and hFXR2 cDNAs were double digested with 
EcoRI and BglII. All three double digested cDNAs were then ligated singly into 
digested pUAS-T vectors to generate pUAS-hFMR1, pUAS-hFXR1, and pUAS-
hFXR2.  A MYC tag was generated using the following oligos: hFMR1 (5-
AAGAATTCATGGAACAGAAACTGATTAGCGAAGAAGATCTGGAATTCAA-3 
and the reverse complement); hFXR1 (5-AAGAATTCAT 
GGAACAGAAACTGATTAGCGAAGAGGATCTGAGATCTAAA-3 and the 
reverse complement); hFXR2 (5-
AAGAATTCATGGAACAGAAACTGATTAGCGAAGAAG ATCTGAGAATTCAA-3 
and the reverse complement).  Oligos were boiled for five mins and allowed to 
cool to 25C for 1 hr.  The product was digested with EcoRI and ligated into the 
similarly digested pUAST vectors already containing human cDNAs. The final 
plasmids were purified, sequenced and microinjected into w1118 embryos by 
Genetic Services, Inc. Transformants with stably integrated genomic inserts were 
identified and mapped to chromosome locations using standard genetic 
techniques. Multiple transgenic lines were isolated for pUAS-MYC-hFMR1, 
pUAS-MYC-hFXR1 and pUAS-MYC-hFXR2. In all assays, two independent 
inserts were assayed for each of the three human transgenic lines. 
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Western blot analyses 
 Western blots were performed as described previously (Tessier and 
Broadie, 2008). In brief, a pool of 4-6 heads was homogenized in 1X NuPage 
sample buffer (Invitrogen, Carlsbad, CA) supplemented with 40 mM DTT.  Debris 
was pelleted by centrifugation at 12,000 rpm at 25C and samples boiled for 5 
mins. Extracts were loaded onto a 4-12% Bis-Tris gel, electrophoresed and 
transferred to nitrocellulose. Membranes were rinsed once with NanoPure water, 
blocked for 1 hr in Odyssey Blocking Buffer (Li-Cor, Lincoln, NE) and probed for 
12-16 hrs at 4C with primary antibodies. Antibodies used include: anti-dFMRP 
(1:3000; 6A15, Sigma, St. Louis, MO), anti--Tubulin (1:400,000; B512, Sigma), 
anti-MYC (1:15; 9E10, Drosophila Studies Hybridoma Bank (DSHB), Iowa City, 
IA) and anti-MYC (1:1000; 71D10, Cell Signaling Technology, Danvers, MA, 
USA). Blots were washed with 0.1% Triton-X 100 in PBS (PBST) and then 
probed for 1 hr at 25C with secondary antibodies. Antibodies used include: 
Alexa Fluor 680-conjugated goat anti-mouse (1:10,000) and Alexa Fluor 680-
conjugated goat anti-rabbit (1:10,000), both from Invitrogen-Molecular Probes 
(Carlsbad, CA). Blots were imaged using the Odyssey Infrared Imaging System 
(Li-Cor, Lincoln, NE).  Raw integrated intensities were calculated, with levels 
were normalized to -Tubulin.  
 
Protein extraction and assay 
 Brain protein concentrations were determined as described previously 
(Tessier and Broadie, 2008). In brief, adult Drosophila heads (0-7 hours old) 
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were rapidly frozen in liquid nitrogen and then stored at -80C. Protein was 
extracted from 10-20 pooled heads by homogenizing in 8M Urea, 1% SDS 
supplemented with 1X Complete Protease Inhibitor Cocktail (Roche). The 
homogenate was incubated at 60C for 1 hr. Protein concentrations were 
determined using a MicroBCA Assay (Pierce, Rockford, IL).  All concentrations 
are reported as mean g protein per head. 
 
Immunohistochemistry 
 Adult brains, testes, and third instar larvae were dissected and fixed for 
immunolabeling as described previously (Gatto and Broadie, 2008; Tessier and 
Broadie, 2008). In brief, all tissues were fixed for 40 mins with 4% 
paraformaldehyde in PBS (pH 7.4).  Preparations were then rinsed with PBS, 
blocked and permeabilized with 0.1% Triton X-100 in PBS (PBST) containing 1% 
bovine serum albumin (BSA) for 1 hr at 25C.  Primary and secondary antibodies 
were diluted in PBST/BSA and incubated 12-16 hrs at 4C and 2 hrs at 25C, 
respectively. Primary antibodies used:  anti-dFMRP (1:500; 6A15, mouse, 
Sigma), anti-pigment dispersing factor (PDF) (1:5; C7 mouse, DSHB), anti-Discs 
Large (DLG) (1:200; 4F3, mouse, DSHB), anti-horseradish peroxidase (HRP) 
(1:250; rabbit, Sigma), anti-GFP (1:50,000; clone 290, rabbit, Abcam, 
Cambridge, MA), and anti-MYC (1:15; 9E10, mouse, DSHB) (1:500; 71D10, 
mouse, Cell Signaling Technology). Secondary antibodies used were Alexa Fluor 
488-conjugated goat anti-mouse IgG and Alexa Fluor 594-conjugated goat anti-
rabbit IgG, both from Invitrogen-Molecular Probes. Preparations were mounted in 
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FluoroMount G (EMS, Hatfield, PA, USA). All fluorescent images were collected 
using an upright Zeiss LSM 510 META laser-scanning confocal microscope. 
Images presented as maximum z-projections.   
 
Clock neuron analyses 
 Brains from staged adult animals were dissected in standard saline and 
then fixed for 40 minutes with 4% paraformaldehyde/ in PBS, pH 7.4.  Dissected 
brains were blocked and permeablized with 0.2% triton X-100 in PBS (PBST) 
supplemented with 1% bovine serum albumin (BSA) for 1 hr at RT. The small 
ventrolateral (sLNv) clock neurons were labeled with anti-PDF antibody staining 
with Alexa-Fluor secondary (1:250; Invitrogen-Molecular Probes). Primary and 
secondary antibodies were diluted in PBST with 0.2% BSA and incubated 
overnight at 4C and 2 hrs at RT, respectively. All fluorescent images were 
collected using a Zeiss confocal microscope. The total number of PDF-positive 
synaptic punctae (>1 m diameter) were counted for each sLNv terminal 
projection on the right and left hemispheres of the brain, for each n=1. 
 
Neuromuscular junction structural analyses 
 The neuromuscular junction (NMJ) of wandering third instar larvae was 
quantified for structural features as described previously (Gatto and Broadie, 
2008). In brief, the muscle 4 NMJ of abdominal segment 3 (A3) was used for all 
quantification. Values were determined for both left and right A3 hemi-segments, 
and then averaged for each animal (n=1). Synapse area was measured as the 
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maximal cross-sectional area in a maximum projection of each collected z-stack. 
A synaptic branch was defined as an axonal projection with at least two synaptic 
boutons.  Synaptic bouton classes defined included i) type Ib (>2 m diameter) 
and ii) mini/satellite (2 m diameter and directly attached to a type Ib bouton).  
Each class is reported as number per terminal. ImageJ (http://rsbweb.nih.gov/ij/) 
was used for automated regional outline and area calculation. 
 
Fecundity measurements 
 Transgene expression was driven in the male germline with a nanos-
GAL4 driver line (nos-GAL4; (Schulz et al., 2004)). Assays of male fecundity 
were done as previously described (Zhang et al., 2004). In brief, for brooding 
tests, individual males (n>8) of each genotype were mated to virgin w1118 females 
(n=3) at 25C, and mated animals were removed from vials after 9 days. Adult 
progeny from individual vials were then counted for a subsequent 9 days. 
 
Electron microscopy 
 Ultrastructural analyses of Drosophila testes were done as previously 
described (Zhang et al., 2004).  In brief, testes from young adults (<24 hrs post-
eclosion) were dissected in PBS and fixed in 2% glutaraldehyde in PBS (pH 7.4) 
for 1 hr.  For light imaging, testes were processed for anti-MYC labeling, as 
above. For EM, preparations were washed in PBS for 10 mins (2X) and then 
incubated in tannic acid for 30 mins to increase membrane contrast. Preparations 
were then transferred to 1% OsO4 in PBS for
 2 hrs, and washed in dH2O for 10 
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mins (3X).  Following secondary fixation, preparations were stained en bloc with 
aqueous 1% uranyl acetate for 1 hr, washed in dH2O (3X) and then dehydrated 
through an ethanol series (50 – 100%).  Finally, samples were passed through 
propylene oxide as a transition solvent using a 1:1 araldite:propylene oxide 
mixture. The solution was replaced with pure araldite and put under vacuum at 
25hg for 1 hr.  Samples were put into fresh resin and placed into a 60C oven 
overnight.  Ultrathin sections (55 – 65 nm) were obtained on a Leica (Wetzlar, 
Germany) UCT Ultracut microtome and transferred to Formvar–coated grids.  
Grids were examined on a Phillips CM10 TEM at 80V and images captured with 
an AMT 2 mega pixel camera. For quantification, sections were taken at a 
magnification of 19,000X or 25,000X and scored for axoneme microtubule 
morphology. 
 
Statistics 
 All statistical analyses were performed using GraphPad InStat 3 
(GraphPad Software, San Diego, CA). Unpaired, nonparametric Tukey-Kramer 
multiple comparisons tests were used to compare means and were applied in 
parallel to all control, dfmr1 null and transgenic construct lines. Significance 
levels in figures are represented as P<0.05 (*), P<0.01 (**) and P<0.001 (***). All 
error bars represent standard error of the mean (s.e.m.) for independent trials. 
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Abstract 
 Fragile X syndrome (FXS), caused by loss of the Fragile X Mental 
Retardation 1 (FMR1) gene product (FMRP), is the most common heritable 
cause of intellectual disability and autism spectrum disorders. It has been long 
hypothesized that the phosphorylation of serine 500 (S500) in human FMRP 
controls its function as an RNA-binding translational repressor. To test this 
hypothesis in vivo, we employed neuronally targeted expression of three human 
FMR1 transgenes, including wildtype (hFMR1), dephosphomimetic (S500A-
hFMR1) and phosphomimetic (S500D-hFMR1), in the Drosophila FXS disease 
model to investigate phosphorylation requirements. At the molecular level, dfmr1 
null mutants exhibit elevated brain protein levels due to loss of translational 
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repressor activity. This defect is rescued for an individual target protein and 
across the population of brain proteins by the phosphomimetic, whereas the 
dephosphomimetic phenocopies the null condition. At the cellular level, dfmr1 
null synapse architecture exhibits increased area, branching and bouton number. 
The phosphomimetic fully rescues these synaptogenesis defects, whereas the 
dephosphomimetic provides no rescue. The presence of Futsch-positive 
(microtubule-associated MAP1B protein) supernumerary microtubule loops is 
elevated in dfmr1 null synapses. The human phosphomimetic restores normal 
Futsch loops, whereas the dephosphomimetic provides no activity. At the 
behavioral level, dfmr1 null mutants exhibit strongly impaired olfactory 
associative learning. The human phosphomimetic targeted only to the brain 
learning center restores normal learning ability, whereas the dephosphomimetic 
provides absolutely no rescue. We conclude that human FMRP S500 
phosphorylation is necessary for its in vivo function as a neuronal translational 
repressor and regulator of synaptic architecture, and for the manifestation of 
FMRP-dependent learning behavior.  
 
Introduction 
Fragile X syndrome (FXS) is the most common monogenic cause of 
intellectual disability and autism (Clifford et al., 2007; Cohen et al., 2005; Fisch et 
al., 2002; Hagerman et al., 2005; Rogers et al., 2001), with an estimated 
prevalence of ~1:4000 males and ~1:6000 females (Koukoui and Chaudhuri, 
2007; Penagarikano et al., 2007). The X-linked neurodevelopmental disorder is 
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caused by loss of fragile X mental retardation 1 (FMR1) gene function, most 
frequently via expansion of a CGG trinucleotide repeat (>200 repeats) in the 5 
UTR leading to subsequent hypermethylation, transcriptional silencing, and loss 
of the FMRP gene product (Heitz et al., 1992; Oberle et al., 1991; Pieretti et al., 
1991). FMRP has three well-defined RNA-binding domains, including KH1/2 
domains (heterogeneous nuclear ribonucleoprotein K homology) (Siomi et al., 
1993) and RGG box (containing repeats of an Arg-Gly-Gly motif) (Darnell et al., 
2001). Consistent with its ability to bind mRNA, FMRP regulates transcript 
trafficking and functions as a negative regulator of translation (Dictenberg et al., 
2008; Estes et al., 2008; Laggerbauer et al., 2001; Mazroui et al., 2002). In Fmr1 
null mice, rates of cerebral protein synthesis are increased (Qin et al., 2005), 
showing that FMRP acts as a negative regulator of translation in vivo. FMRP is 
phosphorylated on a specific serine (human S500; murine S499; Drosophila 
S406) that is N-terminal to the RGG box (Ceman et al., 2003). Following 
phosphorylation of this residue, hierarchical phosphorylation occurs on two 
neighboring serines. In a phosphomimetic, the negative charge from the aspartic 
acid substitution at mouse S499 has been shown to be necessary and sufficient 
for FMRP function in vitro (Ceman et al., 2003). This phosphorylation switch is 
widely hypothesized to control the activity of FMRP as a translational repressor 
modulating neuronal function and behavioral output. 
Post-mortem analyses of FXS patient brains reveal abnormal synaptic 
architecture (Irwin et al., 2000; Irwin et al., 2001a). The hallmark of the disease 
state is an increase in postsynaptic dendritic spines with immature morphology, 
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and a decrease in spines with mature morphology. In particular, neocortical 
pyramidal cells in FXS patients exhibit significant elevation of long dendritic 
spines and fewer mature dendritic spines compared to control subjects (Irwin et 
al., 2000; Irwin et al., 2001a). These changes in synaptic architecture are thought 
to underlie the major behavioral symptoms of the FXS disease state, including 
cognitive dysfunction and learning disabilities (Gallagher and Hallahan, 2011; 
Mercaldo et al., 2009; Rousseau et al., 1994). FXS has been extensively 
investigated in both vertebrate and invertebrate genetic model systems (Bassell 
and Warren, 2008; Bhogal and Jongens, 2010; Gatto and Broadie, 2009a). Both 
Drosophila and mouse disease models exhibit loss of translational control with 
elevated brain protein levels, synaptic architecture defects and deficits in learning 
abilities (Bolduc et al., 2008; Dictenberg et al., 2008; Muddashetty et al., 2011; 
Nakamoto et al., 2007; Narayanan et al., 2008; Pan et al., 2008; Pan et al., 2004; 
Tessier and Broadie, 2008). Recent studies have shown that phosphorylation of 
FMRP modulates miR-125a regulation of PSD-95 mRNA translation 
(Muddashetty et al., 2011). Using the murine phosphomimetic S499D, this work 
shows significantly reduced PSD-95 protein levels, while expression of the 
dephosphomimetic S499A had no effect on levels. This work indicates the critical 
role of S499 in mediating the inhibition and mGluR-mediated activation of PSD-
95 mRNA translation involving miR-125a (Muddashetty et al., 2011). Data 
suggests that dephosphorylation of FMRP is an essential step for subsequent 
dissociation of RISC from FMRP-bound PSD-95 mRNA and activates mRNA 
translation. We have shown previously that introduction of human FMRP into the 
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Drosophila FXS model rescues all defects (Coffee et al., 2010), demonstrating 
functional conservation. This enables us to now pursue systematic structure-
function analyses of human FMRP within the genetically malleable Drosophila 
system. Here, we investigate for the first time the in vivo requirements of S500 
phosphorylation in human FMRP. 
In this study, we generate dephosphomimetic and phosphomimetic 
transgenes (S500A-hFMR1 and S500D-hFMR1, respectively) transformed into 
the Drosophila FXS disease model (Zhang et al., 2001). Both mutant transgenic 
conditions are compared with the dfmr1 null mutant alone (negative control) or 
containing the wildtype human FMR1 transgene (positive control), with 
expression targeted by GAL4 drivers specific to neurons and specific brain 
regions. Each human transgene is investigated in two independent transgenic 
lines in the dfmr1 null mutant background. A wide-ranging series of phenotypic 
tests at the molecular (Tessier and Broadie, 2008), cellular (Gatto and Broadie, 
2008; Pan et al., 2008) and behavioral (Bolduc et al., 2008) levels were selected 
to survey functional requirements in the nervous system. The results show that 
the transgene mimicking constitutive phosphorylation of the serine 500 residue, 
S500D-hFMR1, has the ability to completely rescue a full range of FXS neuronal 
defects. Only S500D-hFMR1 is able to restore normal brain protein levels and 
synaptic architecture in dfmr1 null neurons. S500A-hFMR1 completely lacks this 
ability to compensate, mimicking the dfmr1 null condition. Moreover, S500D-
hFMR1 successfully rescues learning performance back to wildtype levels in a 
Pavlovian olfactory learning assay. In contrast, S500A-hFMR1 is unable to 
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rescue learning deficits and is just as impaired as the complete loss of FMRP 
condition. These results clearly indicate that phosphorylation of a unique, site-
specific serine (S500) within human FMRP is necessary for FMRP function in 
vivo.  
 
Results 
Transgenic constructs with targeted pan-neuronal expression 
 Human, murine and Drosophila FMRP are all similarly phosphorylated on 
a specific, conserved serine residue N-terminal to the RGG box; human S500, 
murine S499 and Drosophila S406 (Ceman et al., 2003; Siomi et al., 1993). 
Phosphorylation of this key serine is proposed to switch FMRP from a resting 
state to an active state as a negative translational regulator (Bassell and Warren, 
2008; Pfeiffer and Huber, 2007; Siomi et al., 1993). To test the hypothesis that 
human FMRP function is regulated via S500 phosphorylation, we engineered 
transgenic human cDNA constructs for wildtype hFMR1 (positive control), 
dephosphomimetic (S500A-hFMR1) and phosphomimetic (S500D-hFMR1). We 
then expressed each transgene with a neural-specific driver (elav-GAL4) in the 
Drosophila FXS model (dfmr1 null mutant). Several independent lines were made 
for each transgenic condition. The generation and testing of these transgenic 
animals is illustrated in Figure 14.  
All three cDNA constructs were sub-cloned downstream of the UAS 
promoter sequence (5X UAS; Fig. 14A). A MYC epitope tag was added at the 
amino terminus of each transgene to track transgenic protein expression. Each
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Figure 14. Generation of transgenic constructs with targeted neuronal 
expression. (A) The three UAS transgenic constructs generated and tested in 
this study. The positive control is wildtype human FMR1 (hFMR1). The two 
mimetics are S500A-hFMR1 and S500D-hFMR1. All cDNA transgenic constructs 
are tagged with a MYC epitope in a pUAST (5X UAS) expression vector to follow 
protein expression. In all assays, two independent transgenic lines for each 
human transgenic construct have been analyzed. (B) The embryonic 
transformation and genetic crossing scheme to introduce each stably integrated 
UAS transgene into the dfmr1 null mutant background and then drive expression 
with the pan-neuronal GAL4 driver elav-GAL4. (C) Western blot analyses of 
transgenic protein expression for the hFMR1 line (control) and two independent 
lines of S500A-hFMR1 and S500D-hFMR1 (denoted as i/ii). Expression from 
brain extracts (1-2 day old adult) was tested with anti-MYC against the epitope 
tag common to all four transgenes (see A). Lines were selected for comparable 
-tubulin. (D) Brain 
immunocytochemistry for transgene expression of the hFMR1 line (control) and 
the two mimetics (S500A-hFMR1 and S500D-hFMR1). Drosophila adult brains 
(1-2 days old) probed with anti-MYC to detect the transgene epitope tag. 
Comparable transgene expression occurs in all conditions. 
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construct was microinjected into genetic background control w1118 embryos (Fig. 
14B). Multiple stably integrated genomic lines for each transgene were isolated 
and self-perpetuating stocks generated. Third chromosome transformants were 
recombined onto the dfmr1 null (dfmr150M) background, and a stock was 
produced with TM6GFP serving to balance the recombinant chromosome (Fig. 
14B). In order to assay neuronal phenotypes, all transgenic lines were crossed 
with a stock line homozygous for the pan-neuronal driver elav-GAL4 and 
heterozygous for the dfmr150M allele. The resulting experimental animals were 
homozygous null for dfmr1 harboring a single copy of the UAS transgene and a 
single copy of the elav-GAL4 driver (Fig. 14B). Two independent insertion lines 
for each human transgene were selected for full phenotype analyses, compared 
to w1118 with elav-GAL4 driver alone (wildtype control), the dfmr1 null with elav-
GAL4 driver alone (negative control) or driving UAS-hFMR1 (positive control). 
Thus, eight genetic lines were compared in all subsequent experimental assays. 
The expression of all transgenes was compared with a combination of 
brain Western blots and brain immunocytochemistry imaging for the common 
MYC epitope tag (Fig. 14C,D). Endogenous Drosophila FMRP expression is 
ubiquitous in neurons and relatively uniform between neurons throughout the 
wildtype brain (Coffee et al., 2010). We therefore selected elav-GAL4 as the best 
described pan-neuronal driver mimicking this expression (Gatto and Broadie, 
2009a). Transgenic lines with low and high elav-GAL4 driven expression 
comparable to matched UAS-hFMR1 positive controls were selected (Fig. 14C), 
and two independent insertion lines with comparable expression for each 
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transgene used for detailed analyses. Western blot analyses of brain protein 
extracts show comparable MYC epitope tag low/high expression levels across all 
selected transgenic genotypes (Fig. 14C). Anti-MYC labeling of brains from all 
three transgenic conditions showed comparable transgene expression levels and 
protein distribution across genotypes (Fig. 14D). Importantly, the UAS-hFMR1 
positive control was indistinguishable from the two mimetic human transgenes in 
brain expression profile (Fig. 14D). Matched lines were thus selected to 
systematically test their ability to rescue a wide range of dfmr1 null mutant 
phenotypes.  
 
Only S500D-hFMR1 restores brain protein translation levels 
 In both rodents and Drosophila, FMRP acts as a negative regulator of 
protein synthesis in neurons (Lu et al., 2004; Reeve et al., 2005; Schutt et al., 
2009; Zhang et al., 2001). Loss of FMRP-dependent translational regulation is 
believed to be the root cause of all FXS impairments. In the dfmr1 null mutant 
condition, the specific target Chickadee (homolog of actin-binding Profilin) and 
total brain protein levels are significantly elevated during key stages of synaptic 
development and refinement, particularly in the immature brain shortly following 
eclosion (Coffee et al., 2010; Tessier and Broadie, 2008). We therefore first 
examined if these fundamental molecular defects could be differentially rescued 
by the hFMR1 phosphomimetic vs. dephosphomimetic proteins. The dfmr1 null 
mutant brain is unaltered in size and gross architecture compared to wildtype and 
genetic controls (Coffee et al., 2010). Lysates from single Drosophila heads were 
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analyzed at the developmental time window of 0-3 hours post-eclosion (25ºC) to 
compare Chickadee expression levels among genotypes. Total protein was 
extracted from developmentally-staged heads at 0-7 hours post-eclosion (25ºC) 
to compare gross protein levels among genotypes. Eight independent genetic 
lines were analyzed in parallel; the wildtype control, dfmr1 null mutant (negative 
control), wildtype UAS-hFMR1 in the dfmr1 null background (positive control) and 
two independent lines for the phosphomimetic and dephosphomimetic 
transgenes.  
In order to confirm that hFMRP is indeed phosphorylated in our transgenic 
animals, we first analyzed Western blots for phospho-hFMRP expression in brain 
extracts (Fig. 15A). The phospho-specific antibody specifically detects 
phosphorylation of the targeted amino acid residue S500. Two independent 
wildtype UAS-hFMR1 lines showed robust phosphorylation at S500, revealing 
that human FMRP is phosphorylated normally in the Drosophila brain (Fig. 15A). 
Next we examined two lines of both the phosphomimetic and dephosphomimetic 
transgenes. As expected, neither S500A nor S500D have detectable bands, 
denoting phosphorylation does not occur at these residues due to the introduced 
point mutations (Fig. 15A). A MYC antibody was used to compare protein-loading 
levels among the genotypes, confirming an equal comparison. We then turned 
our attention to a well-known FMRP target, Chickadee/Profilin, to assess the 
function of the mimetics at the level of a single protein. Chickadee protein levels 
are elevated in the dfmr1 null animals compared to w1118 control (Fig. 15B). Both 
hFMR1 and S500D-hFMR1 were able to restore Chickadee protein levels to 
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Figure 15. S500D-hFMR1 rescues elevated brain protein levels in dfmr1 
null. (A) Representative Western blot of S500 phosphorylation state of wildtype 
hFMR1 and the two mimetic transgenes in the dfmr1 null (dfmr150M) Drosophila 
brain. Brain extracts (2 days old) were probed with anti-phospho-FMRP and anti-
MYC to control for levels of protein. The two independent lines for each genotype 
are denoted as i/ii. (B) Representative Western blot of Chickadee expression 
levels in wildtype control, dfmr1 null and the three human transgenic lines. Brain 
extracts (0-3 hour post eclosion) were probed with anti-Chickadee, with anti--
tubulin used for protein loading control (C) Total brain protein was extracted from 
young adult (0-7 hour post-eclosion) animals and quantified with a MicroBCA 
assay. The five genotypes compared are w1118 control, dfmr1 null (dfmr150M) and 
elav-GAL4 driving UAS-hFMR1 (positive control) and two independent lines each 
of UAS-S500A-hFMR1 and UAS-S500D-hFMR1 (light and dark gray bars) in the 
dfmr1 null background. Each bar shows the average protein (g per head). 
Sample size: 10-20 pooled heads per sample, n=8. Significance: ***P<0.001.  
 93 
control brain levels. The dephosphomimetic, S500A-hFMR1, was unable to 
restore the level of protein expression and mimics the dfmr1 null condition (Fig. 
15B). A tubulin antibody was used to compare protein-loading levels among the 
genotypes, confirming an equal comparison (Fig. 15B).  
We next measured gross brain protein levels in all five genotypes. Null 
dfmr1 mutants with the elav-GAL4 driver alone (elav/+; dfmr150M/dfmr150M) have 
~20% higher brain protein levels compared to genetic controls (elav-GAL4/+) 
(Fig. 15C). Protein levels per head were 17.30.33 g in control compared to 
20.20.43 g in the null mutant (P<0.001, n=8). The positive transgenic control, 
elav-GAL4 driven UAS-hFMR1 in the null mutant background, displayed protein 
levels of 18.00.36 g per head, showing rescue to control levels (not 
significantly different from wildtype, n=8; Fig. 15C). Both independent UAS-
hFMR1 lines (light and dark bars) restored brain protein levels indistinguishable 
from wildtype control (18.10.36 g, 18.00.38 g; not significantly different from 
wildtype, n=8). Both dephosphomimetic lines, UAS-S500A-hFMR1, exhibited 
elevated brain protein levels comparable to dfmr1 nulls, with no indication of 
rescue. The two independent lines showed levels of 21.10.51 g and 20.90.23 
g per head, significantly increased from positive controls (P<0.001, n=8; Fig. 
15C). In sharp contrast, both phosphomimetic lines, UAS-S500D-hFMR1, 
rescued brain protein expression back to control levels. The two independent 
lines showed levels of 18.40.35 g and 17.80.25 g, significantly different from 
dfmr1 null (P<0.001, n=8; Fig. 15C). 
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These results demonstrate that only the phosphomimetic S500D can 
rescue the hallmark elevation of brain protein levels in the dfmr1 null back to the 
control condition. The dephosphomimetic S500A is unable to restore normal 
brain protein levels, which remain elevated comparable to the dfmr1 null. By 
mimicking the negative charge of a phosphate group with an aspartic acid 
residue on S500, the phosphomimetic thus appears functionally active. In 
contrast, by preventing S500 phosphorylation, the dephosphomimetic appears to 
provide no activity and thus resembles the null protein state. This is the first 
demonstration that S500 phosphorylation is necessary and sufficient in 
controlling the functional state of FMRP as a negative translational regulator in 
the in vivo brain. 
 
Only S500D-hFMR1 restores neuromuscular junction synaptic architecture 
 In the Drosophila FXS model, phenotypes at the glutamatergic 
neuromuscular junction (NMJ) synapse are extremely well characterized (Coffee 
et al., 2010; Gatto and Broadie, 2008; Pan et al., 2008; Zhang et al., 2001). The 
size and accessibility of this synaptic arbor, combined with the wealth of synaptic 
markers and structural information, make this terminal particularly suited to a 
systematic investigation. Null dfmr1 mutants display synaptogenesis defects on 
several levels of synaptic architecture, including elevated synaptic area, 
increased synaptic branching and the formation of supernumerary synaptic 
boutons. Most strikingly, developmentally arrested satellite boutons accumulate 
in the absence of FMRP function (Coffee et al., 2010; Gatto and Broadie, 2008), 
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which represent an early stage of normal bouton maturation (Beumer et al., 
1999; Gorczyca et al., 2007; Ruiz-Canada et al., 2004). To compare synaptic 
structure in transgenic animals, we co-labeled wandering third instar larval NMJs 
with presynaptic (HRP membrane marker) and postsynaptic (DLG scaffold 
marker) antibody probes. We then quantified synaptic morphology in the wildtype 
control, dfmr1 null, elav-GAL4 (presynaptic) driven UAS-hFMR1 positive control, 
and the phosphomimetic and dephosphomimetic transgenes in the dfmr1 null 
mutant background. 
Labeling for anti-HRP delineates the innervating presynaptic neuron (red), 
and co-labeling with anti-DLG reveals the postsynaptic domain (green) of the 
target muscle (Fig. 16A). The positive transgenic control of elav-GAL4 driven 
UAS-hFMR1 fully rescued both the enlarged junctional area and increased 
synaptic branching that characterizes the dfmr1 null condition (Fig. 16B, C). To 
quantify synaptic area, the junction delimited by DLG expression was measured. 
The dfmr1 null mutation resulted in a significant increase in synaptic area 
(control, 228.45.4 m2; dfmr1 null, 357.615.1 m2; n>10, P<0.001; Fig. 16B), 
while presynaptic wildtype human FMR1 expression in the null mutant 
background completely restored junctional area to control levels (236.36.9 m2; 
n>10, not significantly different from wildtype; Fig. 16B). To quantify branching, 
HRP-labeled synaptic arbor projections with more than two boutons were 
counted. There was a significant increase in branching in the dfmr1 mutants 
(control, 2.00.17; dfmr1 null 3.10.16; n>10, P<0.001; Fig. 16C). Presynaptic 
hFMR1 expression completely restored synaptic branching from the elevated
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Figure 16. S500D-hFMR1 rescues NMJ synapse architecture in dfmr1 null 
mutant. The wandering third instar NMJ synapse was co-labeled with 
presynaptic and postsynaptic markers and compared among the five genotypes: 
wild-type control, dfmr1 null and elav-GAL4 driven expression in the dfmr1 null 
background of hFMR1 (positive control) and two independent lines each of 
S500A-hFMR1 and S500D-hFMR1. (A) Representative images of the muscle 4 
NMJ labeled for presynaptic HRP (red) and postsynaptic DLG (green). Three 
example synaptic arbors are shown for each of the five genotypes. Scale bar: 10 
m. Quantification of synapse junction area measured based on DLG domain 
expression (B) and the number of synaptic branches measured based on HRP 
labeling (C). The two independent lines for each human transgene were not 
significantly different in any case, and were therefore pooled for these 
comparisons. Sample size: n>10 animals. Significance: ***P<0.001.  
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mutant levels (1.90.11 branches; n>10, P<0.001). Strikingly, S500D-hFMR1 
was equally able to restore synaptic junctional area and arbor branching to 
wildtype levels (2524.5 m2 area, 2.00.14 branches; n>10, not significantly 
different from wildtype; Fig. 16B,C). In sharp contrast, the S500A-hFMR1 
dephosphomimetic was unable to restore synaptic area in the null mutant 
(323.710.3 m2; n>10; Fig. 16B). Similarly, S500A-hFMR1 failed to restore 
normal synaptic branch number in the mutant (3.10.13 branches; n>10; Fig. 
16C). Thus, only the S500D-hFMR1 phosphomimetic has the ability to maintain 
gross synaptic architecture, and S500A-hFMR1 dephosphomimetic completely 
lacks this ability. 
FMRP plays a key role in limiting synaptic bouton number and regulating 
the normal rate of bouton differentiation (Coffee et al., 2010; Gatto and Broadie, 
2008; Siller and Broadie, 2011). To quantify mature type Ib bouton number, 
HRP/DLG co-labeled varicosities >2m in minimum diameter were counted 
within individual synaptic arbors (Fig. 17A). Null dfmr1 mutants exhibit a 
significantly increased number of synaptic boutons compared to controls (dfmr1, 
29.70.4; control, 18.70.44; n>10, P<0.001; Fig. 17B). Presynaptic elav-GAL4 
driven expression of the UAS-hFMR1 positive control rescued bouton number 
back to control levels (19.70.35; n>10, not significantly different from wildtype; 
Fig. 17B). Strikingly, S500D-hFMR1 was also able to completely rescue the 
supernumerary synaptic bouton number to the wildtype array (20.00.37 
boutons; n>10, not significantly different from wildtype; Fig. 17B). Conversely, the 
S500A-hFMR1 had little or no impact on synaptic bouton number in the null
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Figure 17. S500D-hFMR1 rescues synapse bouton differentiation in dfmr1 
null. (A) Representative high magnification images of synaptic boutons. Mature 
type 1b boutons defined as >2 m in minimal diameter. Satellite boutons, 
representing an early stage in bouton differentiation, are <2 m diameter and 
directly attached to a mature type 1b bouton (arrows). Developmentally arrested 
satellite boutons accumulate in the dfmr1 null mutant. Quantification of the 
number of mature boutons (B) and satellite boutons (C) per synaptic arbor in the 
five genotypes is shown. The two independent lines for each human transgene 
were not significantly different, and were therefore pooled for these comparisons. 
Sample size: n>10 animals for each genotype. Significance: ***P<0.001 for all 
comparisons. 
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mutant (27.60.49; n>10, P<0.001; Fig. 17B). A key feature of the null mutant 
phenotype is the accumulation of satellite (immature) boutons (Fig. 17A; arrows). 
These boutons were elevated 8-fold in the dfmr1 null compared to genetic 
controls (dfmr1, 3.90.4; control, 0.530.22; n>10, P<0.001; Fig. 17C). The 
positive control hFMR1 was able to rescue satellite bouton number back to 
wildtype levels (0.730.15; n>10, not significantly different from wildtype; Fig. 
17C). Similarly, S500D-hFMR1 was equally able to completely rescue satellite 
bouton number to the wildtype condition (0.80.2 boutons; n>10, not significantly 
different from wildtype; Fig. 17C). Conversely, S500A-hFMR1 failed to restore 
satellite bouton number in the null mutant (3.90.27; n>10, P<0.001; Fig. 17C). 
Thus, only the S500D-hFMR1 phosphomimetic has the ability to regulate 
synaptogenesis and thus maintain fine synaptic architecture, whereas the 
S500A-hFMR1 dephosphomimetic completely lacks this ability and provides no 
activity beyond the null mutant condition.  
 
Only S500D-hFMR1 restores Futsch/MAP1B synaptic cytoskeletal loops 
 Synaptic architecture is highly dependent on the microtubule cytoskeleton, 
which is tightly regulated by the FMRP-target Futsch (MAP1B homolog) (Hummel 
et al., 2000). Futsch/MAP1B is associated with the axonal nerve-terminal 
microtubule cytoskeleton and is necessary for the regulation of normal synaptic 
growth and bouton differentiation (Roos et al., 2000; Ruiz-Canada et al., 2004). 
Futsch/MAP1B translation is negatively regulated by FMRP via a direct mRNA-
binding interaction (Zhang et al., 2001), and excess Futsch-positive microtubule 
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loops accumulate in the synaptic arbor in the dfmr1 null mutant condition (Gatto 
and Broadie, 2008). In order to quantify the number of Futsch loops per synaptic 
junction, wandering third instar larval synaptic arbors were co-labeled with anti-
HRP, to outline the terminal boutons, and with anti-Futsch antibody to reveal 
protein levels and outline microtubule loops (Fig. 18A). 
 Futsch/MAP1B cytoskeletal loops were compared and quantified in all five 
genotypes in parallel (Fig. 18B,C). Only Futsch loops that made a completely 
enclosed circuit (arrowheads) were quantified, with partial-forming loops 
(asterisks) not included in the counts (Fig. 18A). Null dfmr1 mutants exhibit 
significantly increased Futsch synaptic loops compared to controls (dfmr1, 
4.30.41 loops; control, 2.40.21 loops; n>10, P<0.01; Fig. 18B,C). Presynaptic 
elav-GAL4 driven expression of the UAS-hFMR1 positive control completely 
rescued Futsch loop number back to control levels (2.20.3; n>10, not 
significantly different from wildtype; Fig. 18B,C). S500D-hFMR1 was equally able 
to completely rescue synaptic loop number to wildtype levels (2.30.26 loops; 
n>10, not significantly different from wildtype; Fig. 18B,C). Conversely, S500A-
hFMR1 was totally unable to restore synaptic Futsch loop number in the null 
mutant (5.350.54; n>10, P<0.001; Fig. 18B, C). Thus, only the S500D-hFMR1 
phosphomimetic has the ability to correctly regulate synaptic Futsch/MAP1B and 
maintain the synaptic Futsch loop refinement, whereas the S500A-hFMR1 
dephosphomimetic completely lacks this ability and functionally resembles the 
complete absence of FMRP protein. 
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Figure 18. S500D-hFMR1 rescues Futsch/MAP1B loops in dfmr1 null 
synapse. (A) Representative high magnification images of Futsch loops located 
within NMJ synaptic boutons labeled with anti-HRP. Complete loops were 
quantified (arrows), but incomplete loops (asterisks) were not counted. (B) 
Representative images from the five genotypes are shown (loops denoted with 
an arrowhead) with a high magnification inset of the Futsch loops (loop in inset 
denoted with an arrow). (C) Quantification of the number of Futsch-positive loops 
per NMJ terminal. The two independent lines for each human transgene were not 
significantly different, and were therefore pooled for these comparisons. Sample 
size: n>10 animals for each genotype. Significance: ***P<0.001 or **P<0.01.  
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Only S500D-hFMR1 restores brain circuit synaptic architecture 
 The hallmark defect in FXS patients and disease models is inappropriate 
synaptic connectivity in the central brain (Braun and Segal, 2000; Bureau et al., 
2008; Comery et al., 1997; Hanson and Madison, 2007). In both mouse and 
Drosophila models, brain synapse architecture also appears immature or 
developmentally arrested. We therefore next examined synapse architecture in 
the central brain, based on well-established dfmr1 phenotypes. In Drosophila, a 
particularly well-defined system is the circadian clock circuitry, in which the small 
ventrolateral (sLNv) neurons drive pacemaker activity (Grima et al., 2004; Renn 
et al., 1999; Stoleru et al., 2004). Null dfmr1 mutants exhibit strikingly abnormal 
sLNv synaptic architecture with expanded terminals containing supernumerary 
synaptic boutons (Dockendorff et al., 2002; Gatto and Broadie, 2009a; Morales et 
al., 2002; Sofola et al., 2008). These neurons express the neuropeptide Pigment 
Dispersing Factor (PDF) and exhibit a characteristic branching pattern with 
axonal processes projecting dorsally to a defasiculation point in the 
protocerebrum and then synaptic processes extending medially (Helfrich-Forster, 
1995; Helfrich-Forster, 2005). We used anti-PDF labeling on isolated brains to 
examine impacts on these phenotypes in the elav-GAL4 driven UAS-hFMR1 
positive control and the phosphomimetic and dephosphomimetic transgenes in 
the dfmr1 null background. 
 Brains labeled with anti-PDF clearly display the dorsal sLNv projections 
into the protocerebrum (Fig. 19A). At the point of axonal defasiculation, the 
processes split into a localized array comprised of a small synaptic projection at 
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Figure 19. S500D-hFMR1 rescues central brain synapse arbors in dfmr1 
null. (A) Representative images of adult brain small ventrolateral (sLNv) neurons 
labeled with anti-PDF. The low magnification image on the left shows the 
bilaterally symmetrical sLNv projections, terminating in synaptic arbor projections 
(arrow) in the dorsal protocerebrum. The higher magnification images show the 
left side (right panel) synaptic arbors. Representative images shown from the five 
genotypes assayed: w1118 (control), dfmr150M null (dfmr1) and the null 
background with elav-GAL4 driven hFMR1, S500A-hFMR1, and S500D-hFMR1. 
(B) Quantification of the number of PDF-positive boutons per synaptic arbor in 
the five genotypes shown. Sample size: n>10 animals for each genotype. 
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the dorsal horn and into the protocerebrum. These projections are bilaterally 
symmetrical on the two sides of the brain (Fig. 19A). Null dfmr1 animals exhibited 
a highly significant (n10; P<0.001) increase in the individually identifiable 
number of PDF-labeled boutons compared to controls (Fig. 19A,B). Wildtype 
terminals contained a mean of 40.21.2 boutons compared to 70.51.1 in the 
dfmr1 null. Thus, the mutant condition shows a ~75% increase in PDF-positive 
synaptic boutons (Fig. 19B). Expression of wildtype hFMR1 completely rescued 
the synaptic overgrowth and excessive defasiculation characterizing the null 
mutant, and the terminals become clearly more restricted in extent and refined in 
number of synaptic boutons (Fig. 19B). In the positive control, there was 
42.71.0 boutons, a number indistinguishable from control and significantly 
(n10; P<0.001) rescued compared to the dfmr1 null condition (Fig. 19B). Each 
mimetic transgene was next expressed to evaluate rescue of the sLNv synaptic 
arbor defect in dfmr1 nulls. S500D-hFMR1 was able to completely rescue the 
synaptic bouton number to the wildtype level (42.01 boutons; n>10, not 
significantly different from wildtype; Fig. 19B). Conversely, the S500A-hFMR1 
transgenic condition failed to restore synaptic bouton number in the null mutant 
(70.31.1 boutons; n>10, P<0.001; Fig. 19B). Thus, only the S500D-hFMR1 
phosphomimetic has the ability to regulate synaptic architecture, whereas the 
S500A-hFMR1 dephosphomimetic completely lacks this ability and provides no 
discernable activity beyond the null mutant condition.  
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Only S500D-hFMR1 restores associative learning 
 To conclude our tests of FMRP requirements, we assayed a key 
behavioral output. The hallmark of FXS is cognitive dysfunction, including 
learning disabilities (Gallagher and Hallahan, 2011; Mercaldo et al., 2009; 
Rousseau et al., 1994). Likewise, both mouse and Drosophila FXS genetic 
models manifest clear learning impairments (Bolduc et al., 2008; Chang et al., 
2008; Dockendorff et al., 2002; Krueger et al.; Larson et al., 2008; MacLeod et 
al.; McBride et al., 2005). In this study, we employed the best-characterized 
assay for associative learning in Drosophila, olfactory learning dependent on the 
mushroom body (MB) learning center in the central brain. Classical conditioning 
experiments for olfactory learning were employed (Tully et al., 1994; Tully and 
Quinn, 1985). Animals were acclimated in a cylindrical shock tube and then 
exposed to one of two odors (3-octanol or 4-methylcyclohexanol). Following 
training trials pairing one odor with the aversive shock, the animals were then 
lowered into a T-maze choice point between the two odors. Wildtype controls 
have a high learning index with movement toward the un-paired odor, whereas 
dfmr1 null mutants display a highly significant decrease in olfactory learning 
(Bolduc et al., 2008). Here, we assay whether this learning defect can be 
rescued by introduction of human FMRP, and then test the rescue abilities of the 
phosphomimetic and dephosphomimetic transgenes in this behavioral paradigm 
(Fig. 20).  
Each human transgenic line was targeted specifically to the MB learning 
center with the OK107-GAL4 driver (Fig. 20A). The arrows indicate transgenic
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Figure 20. Only S500D-hFMR1 restores olfactory learning in dfmr1 null. (A) 
Representative images of anti-hFMRP brain expression profiles with the 
mushroom body (MB) specific driver OK107-GAL4. Expression specifically 
targeted to the MB Kenyon cells (arrows). (B) Quantification of learning indices 
for each of the five genotypes is shown. Only S500D-hFMR1 restores learning to 
wildtype levels. Sample size: 75-100 animals per n; n=10 for each genotype. 
Significance: ***P<0.001.  
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expression restricted to MB Kenyon cell bodies with high specificity. The intensity 
and distribution of hFMRP was indistinguishable between wildtype and the two 
mimetic conditions (Fig. 20A). In order to evaluate learning performance indices, 
3-octanol and 4-methylcyclohexanol were employed as matched aversive odors. 
Null dfmr1 mutants exhibit a significantly decreased learning index compared to 
controls (dfmr1, 0.100.03; control, 0.400.02; n>10, P<0.001; Fig. 20B). There 
was a 4-fold decrease in learning performance in the absence of FMRP protein. 
MB OK107-GAL4 driven expression of the wildtype hFMR1 positive control 
strongly rescued the null mutant learning index back towards control levels 
(0.310.03; n>10, not significantly different from wildtype; Fig. 20B). Strikingly, 
S500D-hFMR1 was able to completely rescue learning to the wildtype level 
(0.410.05; n>10, not significantly different from wildtype; Fig. 20B). Conversely, 
S500A-hFMR1 was totally unable to restore learning index in the null mutant 
(0.050.03; n>10, P<0.001; Fig. 20B). Learning performance was reduced 8-fold 
when the FMRP protein was present but could not be phosphorylated at S500. 
Thus, only the S500D-hFMR1 phosphomimetic has the ability to rescue the 
severe learning deficit characterizing the dfmr1 null mutants. The S500A-hFMR1 
dephosphomimetic exhibits little learning ability and is functionally equivalent to 
the complete absence of the FMRP protein. 
 
Discussion 
Fragile X syndrome (FXS) is caused solely by loss of human FMRP. It has 
been widely hypothesized that the phosphorylation state of S500 acts as a 
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“switch” to transition human FMRP from an inactive to active state (Ceman et al., 
2003; Cheever and Ceman, 2009; Pfeiffer and Huber, 2007). This hypothesis 
predicts that human FMRP that cannot be phosphorylated will remain functionally 
inactive, equivalent to full protein loss, whereas a constitutively phosphorylated 
protein will be constantly active, but this has never been tested in vivo. To test 
this hypothesis, we expressed both a phosphomimetic (S500D-hFMR1) and a 
dephosphomimetic (S500A-hFMR1) in the well-characterized Drosophila FXS 
model (dfmr1 null mutant; (Gatto and Broadie, 2009b; Tessier and Broadie, 
2009)). We then tested for functional in vivo rescue of a diverse range of null 
mutant phenotypes. Specifically, we assayed core molecular and cellular 
phenotypes in diverse circuits in the neuromusculature and brain, as well as the 
core behavioral defect of learning impairment. Our findings show that the 
phosphorylation of the S500 residue of human FMRP is necessary for protein 
function as a regulator of translation and modulator of synaptic connectivity, 
which, in turn, lays the foundation for normal behavioral output. The 
phosphomimetic, S500D-hFMR1, provides activity that restores normal function 
at all levels, to closely mimic the wildtype state. Since the phosphomimetic 
rescues the morphological defects seen in the dfmr1 null mutants, our data 
suggest that the excess growth may be due to elevated protein synthesis. In 
contrast, the dephosphomimetic, S500A-hFMR1, is incapable of providing any 
functional rescue and closely mimics dfmr1 null phenotypes at molecular, cellular 
and behavioral levels. 
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 FMRP is an mRNA-binding protein best characterized as a negative 
regulator of translation (Laggerbauer et al., 2001; Schutt et al., 2009; Zalfa et al., 
2003; Zhang et al., 2001). FMRP is present in stalled polyribosomes and inhibits 
the translation of mRNA targets (Ceman et al., 2003; Khandjian et al., 2004; 
Napoli et al., 2008; Reeve et al., 2005; Schutt et al., 2009; Stefani et al., 2004; 
Yang et al., 2009). In the absence of FMRP, total protein levels are elevated in 
the Drosophila brain, particularly acutely during the late developmental stages of 
synaptogenesis and early-use synaptic refinement (Tessier and Broadie, 2008). 
The mouse FMR1 knockout similarly exhibits increased protein synthesis in the 
brain (Qin et al., 2005). Phosphorylation mechanisms regulate activity-dependent 
protein synthesis (Routtenberg and Rekart, 2005). Phosphorylated FMRP 
preferentially associates with stalled polyribosomes, whereas non-
phosphorylated FMRP associates with actively translating polyribosomes 
(Ceman et al., 2003). Phosphorylation likely confers a protein-binding site 
conformational change that modulates ribosomal association. Although the 
molecular mechanism by which FMRP stalls ribosomes has not been elucidated, 
it is likely to be dynamic, as it can be acutely reversed by RNA decoys in run-off 
assays (Darnell et al., 2011). This reversibility would most likely be modulated by 
FMRP phosphorylation (Ceman et al., 2003), but could also involve FMRP 
degradation (Hou et al., 2006). We have shown previously that human FMRP is 
just as effective as the native fly protein in restraining brain protein expression, 
although neither of the human paralogs (FXR1, FXR2) provides any activity 
(Coffee et al., 2010). Using targeted neuronal expression, we show here that only 
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the phosphomimetic (S500D-hFMR1) can restore the elevated brain protein 
levels back to the wildtype condition in the Drosophila FXS model. Whereas 
S500D-hFMR1 is both necessary and sufficient for this inhibitory mechanism in 
neurons, S500A-hFMR1 is unable to provide any function. This provides the first 
proof that S500 phosphorylation is an essential prerequisite for FMRP’s function 
as a negative translational regulator in the in vivo brain. 
The hallmark cellular defect in FXS patients, as well as both murine and 
Drosophila disease models, is the over-proliferation of synaptic connections, 
many of which appear to be immature (Grossman et al., 2006; Irwin et al., 2000; 
Irwin et al., 2001b). Although most research has focused on the elevated number 
of postsynaptic dendritic spines, apposing presynaptic bouton specializations 
accumulate in parallel. In the Drosophila FXS model, both presynaptic boutons 
and postsynaptic dendrites are over-grown and over-elaborated in the absence 
of FMRP, and we have demonstrated that this is a FMRP cell-autonomous 
requirement within neurons (Gatto and Broadie, 2008; Pan et al., 2004). Our 
previous studies of the well-characterized NMJ synaptic arbor have established a 
solely presynaptic requirement for FMRP in restraining terminal area, synaptic 
branching and synaptic bouton differentiation (Gatto and Broadie, 2008). Null 
dfmr1 synapses display increased terminal area, synaptic branching and 
supernumerary synaptic boutons (Coffee et al., 2010; Gatto and Broadie, 2008). 
Our work here demonstrates that only the phosphomimetic (S500D-hFMR1) is 
able to curb growth and restore normal synaptic architecture in the dfmr1 null 
mutant. In sharp contrast, the dephosphomimetic (S500A-hFMR1) does not 
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possess this ability to any detectable degree. Thus, phosphorylation is required 
for FMRP function in regulating synapse architecture. 
A defining feature of the overgrown synaptic connections arising in the 
absence of FMRP is that they appear structurally immature. For example, the 
dfmr1 null NMJ is characterized by the accumulation of mini/satellite boutons 
(Coffee et al., 2010; Gatto and Broadie, 2008). These immature boutons 
represent a developmentally arrested state of an otherwise normal stage of 
bouton maturation (Ashley et al., 2005; Beumer et al., 1999; Dickman et al., 
2006; Torroja et al., 1999). In the absence of FMRP, there is a ~50% increase in 
the number of structurally mature boutons, but a striking 8 to 10-fold elevation in 
the abundance of these immature satellite boutons. Only the transgenic 
introduction of hFMR1 and S500D-hFMR1 can overcome this developmental 
arrest, restoring the normal number of mature synaptic boutons and eliminating 
the accumulation of developmentally arrested satellite-boutons. 
Dephosphorylated S500A-hFMR1, in contrast, exhibits no restorative activity in 
synaptic bouton differentiation or in alleviating the synaptogenic arrest. Thus, 
phosphorylation of human FMRP is absolutely required for the protein to regulate 
synaptogenesis. 
We first showed that FMRP acts to translationally repress Futsch/MAP1B, 
and that dfmr1 null synaptic structure defects are rescued by restoring normal 
Futsch expression levels (Zhang et al., 2001). At the Drosophila NMJ, Futsch 
binds microtubule loops in a subset of developing synaptic boutons (Roos et al., 
2000). These Futsch-positive microtubule structures are proposed to regulate 
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synaptic growth and bouton differentiation (Dent and Kalil, 2001; Tanaka and 
Kirschner, 1991). In dfmr1 null mutants, there is an increased number of Futsch-
positive loops throughout the overgrown synaptic arbor, and these 
supernumerary structures are removed by presynaptic FMRP expression (Gatto 
and Broadie, 2008). This current study shows a doubling in the number of Futsch 
loops in the absence of FMRP, compared to wildtype control. Only the transgenic 
introduction of hFMR1 and S500D-hFMR1 can overcome this Futsch elevation, 
restoring the normal number of Futsch-positive loops in mutant synapses. 
Dephosphorylated S500A-hFMR1, in contrast, exhibits no restorative activity. 
Thus, phosphorylation of human FMRP is absolutely required for the regulation 
of Futsch/MAP1B during synaptogenesis.  
In the Drosophila central brain, the clock circuit is particularly well 
characterized (Chang, 2006; Helfrich-Forster, 2005; Nitabach and Taghert, 
2008). Much attention has focused on the small ventrolateral clock neurons, 
which secrete the neuropeptide PDF and regulate circadian rhythms (Grima et 
al., 2004; Renn et al., 1999; Stoleru et al., 2004). In dfmr1 null mutants, it has 
long been known that these neurons exhibit over-elaborated and over-extended 
synaptic arbors in the protocerebrum (Gatto and Broadie, 2009a; Morales et al., 
2002; Reeve et al., 2005; Sekine et al., 2008), a phenotype strikingly similar to 
the NMJ defect. Introduction of human FMRP can fully rescue this synaptic 
architecture defect. Moreover, only the phosphomimetic (S500D-hFMR1) is able 
to rescue the synaptic defect in the central brain. In contrast, the 
dephosphomimetic (S500A-hFMR1) has absolutely no effect on the null mutant 
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phenotype. Thus, there is the same requirement for human FMRP 
phosphorylation in very distinctive neural circuits: in a peripheral motor circuit and 
in a central brain circuit. These results demonstrate for the first time the absolute 
requirement for FMRP phosphorylation to regulate synaptic connectivity in vivo. 
 The hallmark of FXS is cognitive dysfunction learning disabilities 
(Gallagher and Hallahan, 2011; Mercaldo et al., 2009; Rousseau et al., 1994). 
Consistently, both mouse and Drosophila FXS genetic models manifest clear 
learning impairments (Bolduc et al., 2008; Chang et al., 2008; Dockendorff et al., 
2002; Krueger et al.; Larson et al., 2008; MacLeod et al.; McBride et al., 2005). A 
key brain center of learning in Drosophila is the Mushroom Body (MB) and dfmr1 
null mutants have defects in MB organization ( lobe midline crossing) and 
synaptic connectivity (Bolduc et al., 2008; Michel et al., 2004). Consistently, our 
previous work has shown that dfmr1 null mutants have significant defects in MB-
dependent learning (Bolduc et al., 2008). Wildtype controls learn to move toward 
an odor not paired to electrical shock at a T-maze choice point, whereas dfmr1 
nulls have strong deficits in this associative learning task (Bolduc et al., 2008). 
We show here that MB-targeted expression of human FMRP rescues this defect, 
and that only the phosphomimetic (S500D-hFMR1) maintains this function. In 
contrast, the dephosphomimetic (S500A-hFMR1) has absolutely no effect on the 
null mutant phenotype. These results show that the FMRP functional requirement 
in learning is conserved from man to fly, that this requirement occurs within the 
learning circuit in the central brain, and that phosphorylation of human FMRP at 
S500 is an absolute prerequisite for function in behavioral learning output. The 
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current model is that the FMRP-mRNA complex at the synapse exists in a 
phosphorylated translationally-repressed state until a signal, e.g. mGluR 
activation, triggers FMRP dephosphorylation that leads to a burst of local 
translation. Our data show that mRNAs are over-translated in the presence of an 
unphosphorylated form of FMRP (S500A-hFMRP), but that the phosphomimetic 
constitutively inhibits translation.  
Mouse FMRP is dynamically phosphorylated by ribosomal protein S6 
kinase (S6K1) downstream of the mammalian target of rapamycin (mTOR) 
pathway, and dephosphorylated by the phosphatase PP2A (Narayanan et al., 
2007; Narayanan et al., 2008). In murine hippocampal cultures, the non-
phosphorylatable murine S499A-mFMR1 fails to associate with S6K1. In 
Drosophila, FMRP is phosphorylated in vitro by casein kinase II (Siomi et al., 
2002), although S6K1 might similarly be involved. FMRP was first suggested to 
be a translational repressor in in vitro studies using recombinant FMRP 
(Laggerbauer et al., 2001). Early work on mouse FMRP phosphomimetic and 
dephosphomimetic constructs (S499D and S499A, respectively) has strongly 
suggested that the phosphorylation state regulates translation repressor function 
(Ceman et al., 2003). More recently, loss of hippocampal S6K1 or introduction of 
S499A-FMRP has been shown to similarly elevate expression of SAPAP3, a 
synaptic FMRP target (Narayanan et al., 2008). The current study supports and 
expands on this work, showing a similar phosphorylation requirement for human 
FMRP in the broad context of the Drosophila FXS model. Surprisingly, however, 
the constitutive phosphorylation mimicry achieved by human FMRP S500D is 
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quite adequate to recapitulate wildtype FMRP function in all molecular, cellular 
and behavioral assays pursued here. In vivo FMRP is dynamically 
phosphorylated and dephosphorylated – shuttling between a functional and non-
functional form – in an activity-dependent mechanism (Ceman et al., 2003; 
Cheever and Ceman, 2009; Pfeiffer and Huber, 2007). Why then does the 
S500D transgene not produce gain-of-function phenotypes, or simply fail to 
function? Perhaps animals expressing the FMRP phosphomimetic develop an 
adaptive mechanism in to manage constitutive activation induced by the 
phosphorylation state of the transgenic protein. FMRP is acutely degraded upon 
synaptic stimulation (Gabel et al., 2004), and so one possibility is increased 
FMRP degradation after synaptic stimulation releases the critical subset of 
mRNAs from translation repression. Another possibility is that even though there 
is constitutively mimicked upregulation of the FMRP phosphorylated state, the 
phosphomimetic may not yield activation comparable to native phosphorylation, 
but rather more partial phosphorylation mimicry. Experimentally, while this is the 
best available mimic condition, it is not phosphorylation per se, but rather 
substitution of a phosphate group with a negatively charged aspartic acid 
residue. Thus, the phosphomimetic may enable partial function resembling an 
averaged state between the normal dynamic conformations of phosphorylation 
and dephosphorylation, thereby rescuing near the wildtype level. Of course, this 
explanation does not adequately address the need for a dynamic “switch,” which 
seems dispensable based on all the molecular, cellular and behavioral studies 
presented here.   
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Materials and Methods 
Drosophila stocks and genetics 
 All Drosophila stocks were maintained on standard 
cornmeal/agar/molasses medium at 25C in incubators with a 12 hr light:dark 
cycle. The GAL4 driver lines elav-GAL4 i) (P[GawB]elavC155); ii) 
(P{w[+mC]=GAL4-elav.L}2/CyO) and OK107-GAL4 (P{GawB}ey [OK107]) were 
obtained from the Bloomington Drosophila Stock Center (Bloomington, IN). The 
control genotype was w1118 with a single copy of one of two GAL4 driver lines: 
elav-GAL4/+ (all neuronal assays) and OK107-GAL4/+ (behavioral learning 
assays). The null mutant genotype was homozygous dfmr150M (Zhang et al., 
2001) with a single copy of the two GAL4 driver lines: elav-GAL4/+; dfmr150M and 
dfmr150M; OK107-GAL4/+. As described below, the three transgenic UAS 
constructs generated were UAS-MYC-hFMR1 (positive control), UAS-MYC-
S500A-hFMR1 (dephosphomimetic) and UAS-MYC-S500D-hFMR1 
(phosphomimetic). Third chromosome transformants were recombined with the 
dfmr150M allele by conventional genetic techniques.  
 
Generation of UAS-hFMR1/S500A-hFMR1/S500D-hFMR1 
 An hFMR1 cDNA was subcloned into pBluescript II and used for the 
generation of both amino acid substitution constructs using the QuikChange site-
directed mutagenesis kit (Stratagene, Cedar Creek, TX). Primers used for 
S500A-hFMR1 (alanine at 500) substitution construct: 5-
GAAGCATCAAATGCTGCTGAAACAGAATCTGACCACAGAG AC-3 and the 
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reverse complement. Primers used for S500D-hFMR1 (aspartic acid at 500) 
substitution construct: 5- 
GAAGCATCAAATGCTGATGAAACAGAATCTGACCAC AGAGAC-3 and the 
reverse complement. Substituted cDNA fragments were double digested out of 
pBluescript II with EcoRI and Not1. Each double digested mutation fragment was 
then ligated singly into similarly digested pUAS-T vectors to generate pUAS-
S500A-hFMR1 and pUAS-S500D-hFMR1. A MYC tag was generated using the 
following oligo: 5-
AAGAATTCATGGAACAGAAACTGATTAGCGAAGAAGATCTGGAAT TCAA-3 
and the reverse complement. Oligos were boiled for five mins and allowed to cool 
to 25C for 1 h. The product was digested with EcoRI and ligated into the 
similarly digested pUAS-T vectors already containing the substituted human 
cDNAs. The final plasmids were purified, sequenced and microinjected into w1118 
embryos by Genetic Services, Inc. (Cambridge, MA). Transformants with stably 
integrated cDNA inserts were identified and mapped to chromosome locations 
using standard genetic techniques. Multiple transgenic lines were isolated for 
pUAS-MYC-hFMR1, pUAS-MYC-S500A-hFMR1 and pUAS-MYC-S500D-
hFMR1. In all assays, two independent inserts were assayed for each of the 
three human transgenic lines. 
 
Western blot analyses 
 Western blots were performed as described previously (Coffee et al., 
2010; Tessier and Broadie, 2008). In brief, a pool of 4-6 heads was homogenized 
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in 1X NuPage sample buffer (Invitrogen, Carlsbad, CA) supplemented with 40 
mM DTT. Debris was pelleted by centrifugation at 12,000 rpm at 25C and 
samples boiled for 5 mins. Extracts were loaded onto a 4-12% Bis-Tris gel, 
electrophoresed (1 h. @ 200V) and transferred (1 h. @ 100V) to nitrocellulose. 
Membranes were rinsed once with NanoPure water, blocked for 1 hr in Odyssey 
Blocking Buffer (Li-Cor, Lincoln, NE) and probed for 12-16 hrs at 4C with 
primary antibodies. Antibodies used include: anti-phospho-hFMRP (1 g/ml; 
ab48127, AbCam, Cambridge, MA), anti--Tubulin (1:400,000; B512, Sigma, St. 
Louis, MO), anti-MYC (1:15; 9E10, Drosophila Studies Hybridoma Bank (DSHB), 
Iowa City, IA), anti-Chickadee (1:10; Chi1J, DSHB, Iowa City, IA), and anti-MYC 
(1:1000; 71D10, Cell Signaling Technology, Danvers, MA). Blots were washed 
with THAM/NaCl/NP-40 buffer and then probed for 1 h. at 25C with secondary 
antibodies. Antibodies used include: Alexa Fluor 680-conjugated goat anti-mouse 
(1:10,000) and Alexa Fluor 680-conjugated goat anti-rabbit (1:10,000) 
(Invitrogen-Molecular Probes, Carlsbad, CA). Blots were imaged using the 
Odyssey Infrared Imaging System (Li-Cor). Raw integrated intensities were 
lpha-tubulin.  
 
Protein extraction and assay 
 Brain protein concentrations were determined as described previously 
(Coffee et al., 2010; Tessier and Broadie, 2008). In brief, adult Drosophila heads 
(0-7 hours old) were rapidly frozen in liquid nitrogen and then stored at -80C. 
Protein was extracted from 10-20 pooled heads by homogenizing in 8M Urea, 
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1% SDS supplemented with 1X Complete Protease Inhibitor Cocktail (Roche, 
Indianapolis, IN). The homogenate was incubated at 60C for 1 hr. Protein 
concentrations were determined using a MicroBCA Assay (Pierce, Rockford, IL). 
All concentrations are reported as g protein per head. 
 
Immunocytochemistry 
 Adult brains and third instar larvae were dissected and fixed for 
immunolabeling as described previously (Coffee et al., 2010; Tessier and 
Broadie, 2008). In brief, all tissues were fixed for 40 mins with 4% 
paraformaldehyde in PBS (pH 7.4). Preparations were then rinsed with PBS, 
blocked and permeabilized with 0.2% Triton X-100 in PBS (PBST) containing 1% 
bovine serum albumin (BSA) for 1 h at 25C. Primary and secondary antibodies 
were diluted in PBST/BSA and incubated 12-16 h at 4C and 2 hrs at 25C, 
respectively. Primary antibodies used:  anti-dFMRP (1:500; 6A15, mouse, 
Sigma), anti-pigment dispersing factor (PDF) (1:5; C7 mouse, DSHB), anti-
hFMRP (1:200; mouse, Chemicon, Temecula, CA), anti-Discs Large (DLG) 
(1:200; 4F3, mouse, DSHB), anti-horseradish peroxidase (HRP) (1:250; rabbit, 
Sigma), anti-Futsch (1:200; 22C10, mouse, DSHB), and anti-MYC (1:15; 9E10, 
mouse, DSHB) (1:500; 71D10, rabbit, Cell Signaling Technology). Secondary 
antibodies used were Alexa Fluor 488-conjugated goat anti-mouse IgG and 
Alexa Fluor 594-conjugated goat anti-rabbit IgG, (1:250; Invitrogen-Molecular 
Probes). Preparations were mounted in FluoroMount G (EMS, Hatfield, PA). 
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Fluorescent images were collected using an upright Zeiss LSM 510 META laser-
scanning confocal microscope. Images are presented as maximum z-projections. 
 
Neuromuscular junction analyses 
 The wandering third instar larval NMJ was quantified for structural features 
as described previously (Coffee et al., 2010; Gatto and Broadie, 2008). In brief, 
the muscle 4 NMJ of abdominal segment 3 (A3) was used for all quantification. 
All fluorescent images were collected using a Zeiss confocal microscope. 
Intensity values were determined for both left and right A3 hemi-segments, and 
then averaged for each animal (n=1). Synapse area was measured as the 
maximal cross-sectional area in a maximum projection of each collected z-stack. 
A synaptic branch was defined as an axonal projection with at least two synaptic 
boutons. Synaptic bouton classes defined included i) type Ib (>2 m diameter) 
and ii) mini/satellite (2 m diameter and directly attached to a type Ib bouton). 
Each class is reported as number per terminal. ImageJ (http://rsbweb.nih.gov/ij/) 
was used for automated regional outline and area calculation. 
 
Brain circuit analyses 
 Brains from staged adult animals (zeitgeber time 2-4 h; ZT 2-4) were 
dissected in standard saline and then fixed for 40 minutes with 4% 
paraformaldehyde in PBS, pH 7.4 (Coffee et al., 2010; Gatto and Broadie, 
2009a). Dissected brains were blocked and permeablized with 0.2% triton X-100 
in PBS (PBST) supplemented with 1% bovine serum albumin (BSA) for 1 h at 
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25C. The small ventrolateral (sLNv) clock neurons were labeled with anti-PDF 
antibody staining with Alexa-Fluor secondary (1:250; Invitrogen-Molecular 
Probes). Primary and secondary antibodies were diluted in PBST with 0.2% BSA 
and incubated overnight at 4C and 2 h at 25C, respectively. All fluorescent 
images were collected using a Zeiss confocal microscope. The total number of 
PDF-positive synaptic boutons (>1 m diameter) were counted for each sLNv 
terminal projection on the right and left hemispheres of the brain, and then 
averaged for each animal (n=1). 
 
Pavlovian olfactory learning 
 For classical conditioning, Drosophila were raised at 25°C in a 12:12 
light/dark cycle with lights on at 3:00 AM and lights off at 3:00 PM. To avoid 
variation due to circadian modulation (Lyons and Roman, 2009) all flies were 
tested at ZT 14-16. Flies two to four days post-eclosion were used in all assays. 
Training and testing were carried out in a dark box kept between 22-23C and 
humidified to 85-95% humidity. The experiments were performed in dim red light 
provided by a darkroom safelight equipped with a filter that limited wavelengths 
to greater than 600 nm (Kodak 1A or GBX-2, Rochester, NY). Light intensity was 
adjusted with a rheostat to a final intensity of 0.5 E m-2 sec-1. Classical 
conditioning procedures were similar to those used in previous studies (e.g. 
(Bolduc et al., 2008; Tully et al., 1994; Tully and Quinn, 1985)). Seventy-five to 
100 flies were loaded into a cylindrical “shock tube” and acclimated for 2 minutes. 
The flies were then exposed for 1 min to one of two odors diluted in mineral oil: 
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10-3 3-octanol (OCT) or 1.5x10-3 4-methylcyclohexanol (MCH) - carried by an air 
current of 500 ml/min. The concentrations used were experimentally determined 
to be equally aversive to the flies in a T-maze. During exposure to the odor 
serving as the conditioned stimulus (CS+) flies were subjected to a series of 10 
shocks (2.5 seconds, 80V DC) given every 5 seconds via a copper grid that 
covered the inner surface of the tube. Air was then administered for 50 sec to 
flush the tube of residual odor, and the second odor (the control stimulus or CS-) 
was presented without shock. The chamber was again flushed with air for 1 min 
and the flies were gently tapped into a central compartment where they were 
acclimated for 2 min. The central compartment was lowered to the T-maze where 
the flies were exposed to two converging currents of odorant, one from each arm 
of the maze, and given 2 min to choose between the CS+ and the CS- odors. 
Flies were then trapped in the arms of the maze, anesthetized with CO2, and 
counted. In each experiment two groups of flies of identical age and genotype 
were trained and tested, one in which the OCT was used as the CS+ and one in 
which the MCH was the CS+. A learning index (LI) was calculated by taking the 
number of flies who had chosen the arm with the un-shocked odor and 
subtracting by the number of flies who had preferred the arm with the shocked 
odor, and then dividing by the total number of flies within the two arms. To control 
for any residual odor bias, the LI for each experiment was the average of the two 
consecutive trials, one in which MCH was paired with a shock and the second in 
which OCT was paired with the shock. 
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Statistics 
 All statistical analyses were performed using GraphPad InStat 3 
(GraphPad Software, San Diego, CA). Unpaired, nonparametric Tukey-Kramer 
multiple comparisons tests were used to compare means and were applied in 
parallel to all control, dfmr1 null and transgenic construct lines in the dfmr1 null 
background. Significance levels in figures are represented as P<0.05 (*), P<0.01 
(**) and P<0.001 (***). All error bars represent standard error of the mean 
(s.e.m.) for independent trials. 
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CHAPTER IV 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Martin and Bell first described Fragile X syndrome (FXS) in 1943, initially 
as Martin-Bell Syndrome, and reported the first pedigree of any sex-linked form 
of mental retardation (Martin and Bell, 1943). The FMR1 gene was subsequently 
mapped to a ‘fragile site’ – a gap in the metaphase chromosome at position 
Xq27.3 on the X chromosome (Krawczun et al., 1985) – and finally identified 20 
years ago by yeast artificial chromosome (YAC) cloning and shown to be 
adjacent to the massive expansion of the fragile X-related CpG island in the FXS 
patient genome (Verkerk et al., 1991). FMR1 is a highly conserved gene from 
Drosophila to zebrafish to mouse and human, but is not present in the C. elegans 
or yeast genomes. FMR1 is composed of 17 exons, spans ~40 kb of DNA, and 
encodes an mRNA of 3.9 kb. The gene can be highly alternatively spliced, which 
is not typically tissue-specific (Ashley et al., 1993). FMRP expression is fairly 
ubiquitous, but with the most abundant expression in the brain and testes 
(Abitbol et al., 1993; Devys et al., 1993). In addition to the common CGG 
trinucleotide repeat expansion, FXS can also be caused by deletions or single 
point mutations in the FMR1 coding sequence (Gedeon et al., 1992; Hirst et al., 
1995). FXS segregates as an X-linked dominant disorder with reduced 
penetrance, since either sex, when carrying the mutation, may exhibit intellectual 
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disability (Sherman et al., 1985). Fully penetrant males rarely reproduce, and so 
it has been suggested that the frequency of new fragile X mutations may be as 
high as 1 in 3000 germ cells, to maintain the known population frequency (Brown, 
1990).  
 The FMRP RNA-binding protein is associated with polyribosomes and 
also the RISC complex with a known function in translational repression (Ceman 
et al., 2003; Cheever and Ceman, 2009; Darnell et al., 2009; Wang et al., 2008). 
The human genome also encodes two FMR-related proteins, FXR1P and FXR2P. 
All three proteins show ultrastructurally overlapping expression, can be co-
immunoprecipitated, and can associate with many of the same protein partners 
(Bakker et al., 2000; Ceman et al., 1999; Christie et al., 2009; Zhang et al., 1995). 
Both hetero- and homo-dimerization of the three-protein family has been 
proposed to occur (Christie et al., 2009; Tamanini et al., 1999). For example, 
FXR2 has not only been shown to be present in a FMRP complex, but has also 
been shown to be present alone. The Drosophila genome encodes only a single 
homologous gene, dFMR1, and the Drosophila genetic system has been used 
extensively to probe FMRP functions. The extraordinarily well-established 
Drosophila FXS disease model has been incredibly useful in dissecting causative 
mechanisms that may be responsible for disease state symptoms (Banerjee et 
al., 2010; Dockendorff et al., 2002; Estes et al., 2008; Gatto and Broadie, 2008; 
Siller and Broadie, 2011; Tessier and Broadie, 2011).  
 In my first aim, I investigated the evolutionary conservation of the human 
FXS gene family using the Drosophila disease model. Null dfmr1 mutants 
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recapitulate FXS-associated molecular, cellular and behavioral phenotypes, 
suggesting FMR1 function has been conserved, albeit with specific functions 
probably sub-served by the expanded human gene family. For example, mouse 
Fxr1 knockout animals die shortly after birth, owing to defects in cardiac and 
skeletal muscle development (Mientjes et al., 2004). Conversely, both Fmr1 and 
Fxr2 knockouts as well as Fmr1/Fxr2 double knockouts are completely viable. 
Both Fmr1 and Fxr2 knockout mice exhibit some FXS-like phenotypes, albeit 
fairly weakly, including learning defects, hyperactivity and macroorchidism (Chen 
and Toth, 2001; McNaughton et al., 2008). Interestingly, the Fmr1/Fxr2 double 
knockout results in some augmented defects, including exaggerated behavioral 
phenotypes of open-field activity and circadian arrhythmicity (Spencer et al., 
2006; Zhang et al., 2008). To test evolutionary conservation, I used tissue-
targeted transgenic expression of all three human genes (FMR1, FXR1, FXR2) in 
the Drosophila disease model to investigate function at molecular, neuronal and 
non-neuronal levels. In neurons, dfmr1 null mutants exhibit elevated protein 
levels altering central brain and NMJ synaptic architecture, including increased 
synapse area, branching and bouton numbers. hFMR1 can fully rescue both the 
molecular and cellular defects in neurons, comparably to the native dFMR1, 
whereas hFXR1 and hFXR2 provide no rescue. For non-neuronal requirements, I 
assayed male fecundity and testes function. Null dfmr1 mutants are effectively 
sterile due to disruption of the 9+2 microtubule organization in the sperm tail. 
Amazingly, all three human genes fully rescue mutant fecundity and 
spermatogenesis defects. These results indicate that FMR1 gene function is 
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evolutionarily conserved in neural mechanisms and cannot be compensated by 
either FXR1 or FXR2, but that all three proteins can substitute for each other in 
non-neuronal requirements (Coffee et al., 2010).  
 Next, I investigated the hypothesis that the phosphorylation of the serine 
at 500 (S500) in human FMRP controls its function as an RNA-binding 
translational repressor. It has been hypothesized that the phosphorylation state 
of S500 acts as a “switch” to transition FMRP from an inactive to active state 
(Ceman et al., 2003; Pfeiffer and Huber, 2007). This hypothesis predicts that 
FMRP that cannot be phosphorylated will remain functionally inactive, equivalent 
to full protein loss, whereas a constitutively phosphorylated protein will be 
constantly active, but this has never been tested in vivo. Using the Drosophila 
FXS model, I used targeted expression of human FMR1 transgenes, including 
wildtype (hFMR1), dephosphomimetic (S500A-hFMR1), and phosphomimetic 
(S500D-hFMR1) to investigate phosphorylation requirements. Null dfmr1 mutants 
exhibit elevated brain protein levels, overgrowth of synaptic architecture and 
defects in olfactory-based associative learning due to loss of translational 
repressor activity. The human phosphomimetic rescues these defects, while the 
dephosphomimetic phenocopies the disease state.  
Synaptic architecture is highly dependent on the microtubule cytoskeleton, 
which is tightly regulated by the FMRP-target Futsch (MAP1B homolog) (Hummel 
et al., 2000). Futsch is associated with the axonal nerve-terminal microtubule 
cytoskeleton and is necessary for the regulation of normal synaptic growth and 
bouton differentiation (Roos et al., 2000; Ruiz-Canada et al., 2004). It is 
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proposed that Futsch-positive loops are enriched in developing, immature 
synaptic boutons. Futsch translation is negatively regulated by FMRP via a direct 
mRNA-binding interaction, and excess Futsch-positive microtubule loops 
accumulate in the synaptic arbor in the dfmr1 null mutant condition (Gatto and 
Broadie, 2008). At the Drosophila NMJ, Futsch binds microtubule loops in a 
subset of developing synaptic boutons (Roos et al., 2000). These Futsch-positive 
microtubule structures are proposed to regulate synaptic growth and bouton 
differentiation (Dent and Kalil, 2001; Tanaka and Kirschner, 1991). In dfmr1 null 
mutants, there is an increased number of Futsch-positive loops throughout the 
overgrown synaptic arbor, and these supernumerary structures are removed by 
presynaptic FMRP expression. I show a doubling in the number of Futsch loops 
in the absence of FMRP, compared to wildtype control. Only the transgenic 
introduction of hFMR1 and S500D-hFMR1 can overcome this Futsch elevation, 
restoring the normal number of Futsch-positive loops in mutant synapses. 
Dephosphorylated S500A-hFMR1, in contrast, exhibits no restorative activity. I 
conclude that human FMRP S500 phosphorylation is necessary for its in vivo 
function as a neuronal translational repressor and regulator of synaptic 
architecture, and for the manifestation of FMRP-dependent learning behavior 
(Coffee et al., 2011).  
 Taken together, my work has demonstrated that FMR1 is conserved from 
Drosophila to human because hFMR1 rescues all dfmr1 neuronal and non-
neuronal defects assayed in this body of work, whereas hFXR1 and hFXR2 can 
only compensate non-neuronally. One possible mechanism for the divergent 
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roles of the paralogs could be due to the fact that each has varying levels of 
expression in different tissues. While there is overall overlap of expression 
among the family members, FXR1, for example, has elevated expression in 
muscle (Mientjes et al., 2004). Findings from the Fmr1/Fxr2 double knockout 
mouse model suggest FXR2 has at least some overlap in function with FMR1, 
but it is not clear whether this only occurs in a combinatorial fashion with FMR1 
because FXR2 expression levels are unchanged in FXS and do not compensate 
to rescue disease phenotypes (Spencer et al., 2006). Though there is extremely 
high sequence homology among the three family members, the paralogs diverge 
in sequence similarity in their C-terminal ends (Kirkpatrick et al., 2001). This 
could possibly explain the tissue expression differences and divergent function of 
the paralogs as examined in this body of work. Furthermore, I have shown that 
phosphorylation of residue S500 in hFMRP is critically important for the function 
of the protein as a translational repressor. The S500D-hFMR1 phosphomimetic 
rescues neuronal FXS defects, while the dephosphomimetic (S500A-hFMRP) 
phenocopies the FXS disease condition. These studies provide great insight into 
the in vivo function of the FMR1 gene family, and this insight should help to 
elucidate mechanisms for major FXS phenotypes. Further in vivo dissection of 
the functional importance of various hFMRP domains should be performed to 
garner insights into FMRP mechanistic roles in neurons and other cell types.  
 It has previously been shown that one human FXS patient, lacking the 
cytogenetic expression of FRAXA as revealed by folate deprivation cell culture 
experiments and harboring a normal CGG repeat length and unmethylated CpG 
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island, harbors a de novo missense mutation (I304N) within the KH2 RNA-
binding domain (De Boulle et al., 1993). This patient presents with an unusually 
severe FXS phenotype, including severe mental retardation (IQ<20), ‘impressive’ 
macroorchidism and peripheral neuropathy of lower extremities (De Boulle et al., 
1993). A general feature of KH domain-containing proteins is their incorporation 
into RNP (ribonucleoprotein particle) complexes via a RNA-interaction surface 
(Leffers et al., 1995). The 1304N mutation has been reported to unfold the FMR1 
KH2 domain, leading to disturbance of the normal interactions within the 
corresponding RNP complexes and an abrogation of RNA binding, at least at 
high salt concentrations (Siomi et al., 1994). However, at physiological salt 
conditions, RNA-binding activity of this missense mutation is not abolished to 
cytoplasmic mRNAs or to RNA homopolymers (Siomi et al., 1994). Instead of 
causing impaired RNA binding, the I304N mutation abolishes the association of 
FMRP with polyribosomes, suggesting the KH domain is important in FMRP-
polyribosome association in vivo (Feng et al., 1997). Therefore, conclusions from 
this study suggest that the mutation phenotype arises in the sequestration of 
mRNAs from their translational regulation by forming nontranslatable mRNP 
particles.  
More recently, it has been suggested that the I304N mutation might have 
a dominant negative effect by affecting the structure of the mRNP complexes 
containing FMRP (Darnell et al., 2005). Darnell and colleagues identified the 
RNA target for the KH2 domain as a sequence-specific element within a complex 
tertiary structured termed the FMRP “kissing complex”, and demonstrated that 
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FMRP association with brain polyribosomes is abrogated by competition with 
kissing complex RNA (Darnell et al., 2005). I have previously sub-cloned the 
I304N-hFMR1 cDNA into the pUAST expression vector and had this construct 
transformed into Drosophila embryos. It would be interesting to analyze this 
transgenic construct in our Drosophila FXS disease model (Coffee et al., 2010; 
Zhang et al., 2001). What array of neuronal vs. non-neuronal phenotypes would 
this transgenic animal be able to rescue when present in the dfmr1 null 
background? Would we observe an exacerbated disease phenotype as was seen 
in the human patient with this mutation? In addition to prior established neuronal 
assays of brain protein levels and synaptic architecture, quantitative RT-PCR and 
Western blots of several known mRNA targets could be conducted in order to 
assess the ability or lack thereof of the mutated KH2 domain in properly 
associating with mRNP complexes and negatively regulating translation. Perhaps 
I would predict that this transgenic animal would phenocopy the disease animal, 
but with an even more severe FXS phenotype. Although to date this mutation has 
only been found in one FXS patient, this case has definitely indicated the value of 
screening for further structure-function mutations within the FMR1 gene that 
could be responsible for modifying the disease state.  
 Another FMRP domain, which, while studied in vitro, should be 
investigated in vivo, is the RGG box domain (Siomi et al., 1993). The RGG box 
associates with G-quartets with nanomolar affinity and is considered to be the 
primary mRNA-binding domain present in FMRP due to the vast majority of 
FMRP targets possessing the G-quartets bound by the RGG box (Darnell et al., 
 132 
2001; Menon and Mihailescu, 2007; Schaeffer et al., 2001). The RGG box has 
been shown to be post-translationally methylated on arginines, which is 
significant because this hints at this domain being able to differentially bind 
potential partners (Stetler et al., 2006). FMRP lacking the RGG box does not 
distribute normally on polyribosome fractions, demonstrating the intact domain is 
critically important for FMRP function and without it, FMRP may not be able to 
function normally as a translational regulator (Mazroui et al., 2003). Since this 
domain is the primary FMRP mRNA-binding domain, it could be expected that 
FMRP would have reduced affinity for mRNA in the absence of the RGG box.  
Recently, the Ceman laboratory has investigated the RGG box arginines 
important for FMRP function and their role in polyribosome and mRNA 
association (Blackwell et al., 2010), and found that arginines 533 and 538 (in 
mouse FMRP) are required for normal FMRP polyribosome association, whereas 
all four arginines (533, 538, 543, 545) play a role in mRNA binding. The model G-
quartet RNA sc1 (Darnell et al., 2001) required arginines 533 and 538 for 
canonical association with FMRP. The second most abundant co-
immunoprecipitating brain mRNA containing a G-quartet is AATYK (Brown et al., 
2001), which does not require the 533/538 arginines for binding (Blackwell et al., 
2010). This suggests that different arginines of the RGG box are involved in 
binding different target mRNAs. Methylation of arginine residues 533 and 538, or 
543 and 545, leads to loss of sc1 RNA binding (Blackwell et al., 2010). However, 
it is still not known whether methylation inhibits mRNA binding or occurs on 
selective arginines to control the selection and specificity of bound RNAs. 
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Proteins can be partially methylated and released from the methyl transferase to 
re-associate later and become fully methylated (Kolbel et al., 2009), in order to 
modulate protein-protein interactions. It would be interesting to determine 
whether FMRP exists in two populations, methylated and unmethylated, or some 
combination of both (Blackwell et al., 2010). If it exists as a collection of proteins 
with distinct methylated arginines, this would allow the cell to express FMRPs 
with varying RNA binding abilities.  
 I have generated an RGG box deletion (RGG) within hFMR1 cDNA and 
sub-cloned this into the pUAST expression vector. In addition to established 
neuronal assays of brain protein levels and synaptic architecture, quantitative 
RT-PCR of known mRNA targets and Western blots of known protein changes 
could be conducted to assess the ability of the RGG box deletion in properly 
associating with mRNP complexes. What array of neuronal vs. non-neuronal 
phenotypes might this transgenic animal be able to rescue in the dfmr1 null 
background? I would predict that due to the RGG box being the major RNA-
binding domain that the RGG-hFMR1 construct would fail to rescue dfmr1 null 
defects in many, if not all, of established neuronal assays. Interestingly, would 
the I304N-hFMR1 construct mimic the RGG-hFMR1 construct? Perhaps many 
of our morphological assays would show similar phenotypes within each of these 
human transgenic lines. However, on the molecular level, I would predict 
differences as these mutations are within two distinct RNA-binding domains. 
Different RNA targets should show differential regulation in each of these 
transgenic models. The comparisons between these two transgenic animals, 
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each predicted to disrupt/delete an mRNA-binding domain, would be extremely 
informative. To date, there are very few in vivo mutational studies that have been 
conducted to assess FMR1 structure-function relationships that may underlie 
defects causative for FXS. Future genetic screens should help reveal additional 
mutations within the FMR1 gene that can cause FXS, including informative point 
mutations within the RGG box.  
 In addition to the neuronal and non-neuronal assays employed in the work, 
as described in Chapters II and III, I have investigated several additional 
phenotypes throughout my thesis work that could be used in the future to provide 
insights into the mechanisms of FXS dysfunction. One assay I have pursued at 
great length involves monitoring circadian activity rhythms using Drosophila 
Activity Monitoring (DAM) Systems (TriKinetics, Waltham, MA). FXS patients 
display disrupted circadian sleep patterns (Gould et al., 2000; Kronk et al., 2010; 
Weiskop et al., 2005), and dfmr1 null mutants similarly display a loss of normal 
circadian rhythms (Inoue et al., 2002). A normal fly is active for 12-14 hours 
during the daylight and virtually inactive for 10-12 hours at night. The sleep 
pattern is strikingly similar to that of humans. If entrained to a light:dark cycle of 
12 hours of light followed by 12 hours of dark (LD12:12) for several days, a wild-
type fly will maintain this normal pattern of activity in total darkness for at least 
several weeks. However, dfmr1 null mutants lack this capacity and display an 
erratic pattern of non-rhythmic activity, punctuated by periodic bouts of 
hyperactivity (Dockendorff et al., 2002). My preliminary actogram data show that 
wild-type flies can be entrained to light and have bimodal activity (in both LD and 
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DD), peak of activity as lights are turned on in the morning, followed by a period 
of rest, and peak of activity as lights are about to be turned off at night (Fig. 21). 
Once entrained to light, wild-type flies are able to predict the onset of darkness 
as evidenced by the activity increase. Wild-type flies exhibit a normal period of 
~23.8 h. and are able to maintain this period for days/weeks in the DD free-
running challenge. In contrast, dfmr1 null mutants, while able to be weakly 
entrained to light, are unable to maintain bimodality and rhythm with the DD 
challenge (Fig. 21). Null flies also exhibit hyperactivity compared to controls as 
measured by the number of infrared beam crosses per day. There is a wealth of 
information that can be attained studying the circadian rhythmicity in the 
Drosophila FXS model. With all of my human transgenic lines, it would be 
extremely interesting to dissect the functions of the human paralogs in 
comparison with hFMR1 in regulating circadian defects and hyperactivity.  
 A second avenue that I have begun to investigate is polyribosome 
association assays (Ceman et al., 2003). FMRP associates with heavy-
sedimenting polyribosome complexes (translating polyribosomes) that contain 
mRNAs bound by multiple ribosomes (Ceman et al., 2003; Khandjian et al., 
1996; Tamanini et al., 1996). Polyribosome association has been shown to be 
critical to FMRP function in the I304N missense mutation condition, with 
disruption in the KH2 domain causing FMRP to no longer associate (Feng et al., 
1997). mRNAs found to be associated with FMRP by immunoprecipitation also 
display altered association with polyribosomes in the absence of FMRP, 
suggesting that FMRP  
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Figure 21. Circadian actograms of control (w1118) and dfmr1 null animals. 
(A) Representative actograms from control flies and (B) mutant flies. Flies that 
had been entrained to a light:dark cycle were placed in the activity monitors for 5 
days in LD, then shifted to constant darkness (DD; shaded area) and their activity 
was recorded for an additional 5 days. Flies expressing dFMR1 have rhythmic 
patterns of rest and activity and maintain these throughout DD, while flies lacking 
wild-type dFMR1 have relatively high activity and are arrhythmic. 
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interacts with the translational machinery to modulate protein expression of 
associated mRNAs (Brown et al., 2001). In vitro work by Ceman and colleagues 
has demonstrated that unphosphorylated FMRP associates with actively 
translating polyribosomes, while phosphorylated FMRP is associated with stalled 
polyribosomes (Ceman et al., 2003). This suggests that phosphorylation 
regulates FMRP polyribosome association and that the release of FMRP-induced 
translational suppression may involve a dephosphorylation signal. A breadth of 
knowledge could be gained by assessing polyribosome association in vivo using 
our established FXS Drosophila model.  
I have conducted preliminary work on polyribosome assays with wild-type 
animals. Briefly, fly head lysates were generated from approximately 1-1.5 mL of 
total heads (as measured in an Eppendorf tube) and overlayed onto a 15-45% 
sucrose gradient. Gradients are then centrifuged for 2 hrs at 188,000g at 4ºC. 
Each gradient was then fractionated into 1 mL fractions by bottom displacement 
using a gradient fractionator with the ribosomal profile monitored at OD254. 
Western blot analysis could also be conducted on the fractions and probed with 
an FMRP antibody in order to determine whether FMRP is located within the 
mRNP complex, associating with polyribosomes, or if it is present in both 
sedimenting fractions. Preliminary data from w1118 control animals show that 
FMRP is primarily associated with the mRNP complex and light polyribosomal 
fractions (Fig. 22). It would be extremely interesting to assay the dephospho- and 
phosphomimetic human transgenic lines in this polyribosome assay. Using a 
translational inhibitor, such as puromycin, polyribosome run-off assays could be  
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Figure 22. Polyribosomal association profile of w1118 control animals. Head 
lysates were prepared and then fractionated on a linear 15-45% sucrose gradient. 
The profile (A) is shown as absorbance at 254 nm. The positions of the 40S, 60S, 
and 80S monosomes are denoted. Wild type FMRP is associated with actively-
translating light-polyribosomes as well as the mRNP complex as seen in the 
Western blot probed with dFMRP (B). 
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conducted in order to assess the location of each of FMRP in these mimetics. I 
would predict the dephosphomimetic would resemble the dfmr1 null condition 
and show ribosome run-off (denoting presence on actively translating 
polyribosomes). Conversely, the phosphomimetic would be predicted to 
resemble the wild-type condition and not show ribosome run-off, suggesting 
FMRP is associating with stalled polyribosomes and inhibiting the translational 
machinery. Utilizing these assays would provide the first in vivo evidence of the 
molecular mechanisms involved in FMRP negative translational regulation.  
 Work presented in this dissertation on the conservation and 
phosphorylation-dependent functions of the human Fragile X syndrome gene 
family has helped to elucidate important control and regulatory mechanisms of 
FMR1 and its associated paralogs. The Drosophila FXS disease model has 
made it possible to conduct these insightful experiments. Combining the 
established neuronal and non-neuronal assays discussed in Chapters II and III, 
with more preliminary assays described in this chapter, a large amount of 
informative future work could be done on the existing human transgenic lines that 
I have made, in order to better understand FMRP function as it relates to this 
pervasive, wide-spectrum neurological disorder.  
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